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1. Abstract 
 
 
1.1. Zusammenfassung 
Hautalterung geht mit der Akkumulation von seneszenten Zellen einher, welche eine chronische Entzündung und 
den Abbau der Extrazellulären Matrix fördern. Autophagie ist ein speziesübergreifend konservierter Prozess, der 
durch den Abbau von alten oder beschädigten Proteinen und Organellen zur Instandhaltung zellulärer Homöostase 
beiträgt. Da dieser Prozess im Zuge des Alterns beeinträchtigt ist, wird angenommen, dass Autophagie eine Rolle 
bei der Entwicklung von Seneszenz spielt. Der Zusammenhang von Autophagie und zellulärer Seneszenz ist 
derzeit unzureichend verstanden und scheint vom Zelltyp, Gewebetyp und der Art und Weise, wie Seneszenz in 
Modellsystemen initiiert wird, abzuhängen. Warum beschädigte Zellen Seneszenz anstelle von Apoptose einleiten 
bleibt eine der Hauptfragestellungen in der Erforschung von altersbedingten Krankheiten. 
 
In dieser Arbeit wurden mittels 2D-LC-MS/MS labeling-assisted proteomics 230 hochregulierte Proteine und 228 
herunterregulierte Proteine in seneszenten normalen humanen dermalen Fibroblasten (NHDF) identifiziert. Unter 
den hochregulierten Proteinen wurden mittels gene set enrichment analysis (GSEA) 27 biologische Prozesse 
identifiziert, die möglicherweise im direkten Zusammenhang mit Autophagie stehen. Unter anderem waren die 
Lysosomen Biogenese, mTOR Signalwege und Makroautophagie erhöht. Dies zeigt, dass Stress-induzierte 
Seneszenz (SIPS) zu einer Erhöhung des Autophagie Flux in NHDF führt. 
Zur Untersuchung der Frage, ob die Erhöhung des Autophagie Flux eine Rolle in der Entwicklung von Seneszenz 
spielt oder eine Folge dieser ist, wurden mehrere Experimente durchgeführt. Die Stimulierung des Autophagie-
Flux in humanen WS1 Fibroblasten mittels Rapamycin vor der Induktion von SIPS konnte diese verzögern, 
wohingegen die Blockierung des Autophagie Flux keinen Effekt zeigte. Die Erhöhung des Autophagie-Flux nach 
der Induktion von SIPS verzögerte ihre Ausbildung, wobei die Blockierung zum Absterben der Zellen führte. Es 
wurde gezeigt, dass dies spezifisch seneszente Zellen betrifft, was auf eine Autophagie-bedingte 
Reprogrammierung zur Apoptose hindeutet. Erste Daten belegen, dass die Anzahl an Mitochondrien und oder 
Calcium Signalwege eine Rolle spielen. Der genaue molekulare Mechanismus muss allerdings noch aufgeklärt 
werden. Die in dieser Arbeit erhobenen Daten weisen auf eine duale gegenläufige Rolle der Autophagie bei der 
Entwicklung von Seneszenz in Hautfibroblasten hin. Siezeigt, dass die Modulation von Autophagie einen 
potenziellen Angriffspunkt zur Bekämpfung von altersbedingten Krankheiten ist. 
In dieser Arbeit wurden außerdem mehrere Kohlenhydrate und deren Derivate auf die Fähigkeit getestet 
Autophagie zu beeinflussen. Raffinose, Sucrose, Isomaltulose, Sorbitol und Methyl-a-glucopyranosid wurden als 
neue mTOR-unabhängige Aktivatoren des Autophagie-Flux identifiziert, wohingegen Trehalose einen 
inhibierenden Effekt zeigte. 
Neben Autophagie wurden mittels GSEA ca. 40 weitere biologische Prozesse identifiziert, die in seneszenten 
NHDF signifikant verstärkt reguliert werden. siRNA vermitteltes Silencing von vier hochregulierten Proteinen 
führte zum Zelltod. Damit konnte gezeigt werden, dass (I) der Alkohol Metabolismus (APOL2), (II) der 
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Fettsäuremetabolismus (CES2), (III) Sauerstoffmangel (MGARP) und die Regulierung des Apoptose Signalwegs 
(PTTG1IP) eine direkte Rolle bei der Entwicklung von Seneszenz spielen. 
 
Das Verständnis der molekularen Zusammenhänge von Seneszenz, Autophagie und Apoptose werden immer 
wichtiger in der Alters- und Krebsforschung. Ein Verständnis, wie diese Prozesse sich gegenseitig regulieren, 
könnte dazu beitragen neue Therapien zur spezifischen Eliminierung von seneszenten Hautfibroblasten zu 
entwickeln. Derzeit gibt es keine robusten spezifischen biologischen Marker zur Identifizierung von seneszenten 
Zellen in vitro und in vivo. Die Identifizierung von neuen Seneszenzmarkern hätte großes diagnostisches und 
therapeutisches Potential. 
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1.2. Abstract 
Skin aging is accompanied by an accumulation of senescent cells, which promote a low chronic inflammation and 
degradation of the extracellular matrix. Autophagy is a conserved biological process involved in cellular 
homeostasis through the recycling of long-lived or damaged proteins and organelles. Impaired during aging, it has 
been speculated that autophagy could be involved in senescence. The role of autophagy in the context of cellular 
senescence remains elusive and is not understood yet, seemingly dependent on the cell type, tissue, and manner 
in which senescence is induced. Why damaged cells resort to senescence instead of apoptosis remains a key 
question in the understanding of aging and age-related pathologies. 
 
In this work, 2D-LC-MS/MS labeling-assisted proteomics identified 230 upregulated and 228 downregulated 
proteins in senescent normal human dermal fibroblasts (NHDF). When upregulated proteins were subjected to 
agenesetenrichmentanalysis(GSEA),    27autophagy-relatedbiologicalprocesseswerefoundenriched,   showing that 
stress-induced premature senescence (SIPS) leads to an increased autophagic activity in senescent NHDF. This 
included biological processes such as lysosome biogenesis, mTOR signaling and macroautophagy. 
Although autophagy is increased in SIPS, whether it is involved in senescence development or a consequence 
remained to be clarified. In WS1 human fibroblasts, rapamycin-mediated stimulation of autophagic flux prior to 
SIPS induction delayed the onset of senescence, whereas its inhibition through chloroquine showed no effect. 
After SIPS induction, stimulation of autophagy delayed the onset of senescence, whereas its inhibition changed 
the cell fate from senescence to cell death. The latter observation was further shown to be specific to senescent 
WS1, suggesting the existence of an autophagy-mediated “apoptotic switch”. Although the exact molecular 
mechanism of this switch remains to be determined, this work implicates mitochondrial abundance and/or mass 
as well as calcium signaling as part of the process. These data highlighted a dual beneficial/detrimental role of 
autophagy in skin fibroblasts senescence and thus its modulation is a potential target for age-related pathologies. 
In this regard, carbohydrates and derivatives have been tested for the ability to modulate autophagy. Whereas 
raffinose, sucrose, isomaltulose, sorbitol and methyl-α-glucopyranoside could be use as novel mTOR- 
independent activators of autophagy, trehalose could have an inhibitory effect. 
Aside from autophagy, GSEA allowed the identification of approximately 40 other biological processes 
significantly enriched in senescent NHDF, some of which could directly be involved in senescent fibroblasts 
immortality. Selection of four upregulated candidates involved in (I) alcohol metabolism (APOL2), (II) fatty acid 
metabolism (CES2), (III) response to hypoxia (MGARP) and (IV) regulation of apoptotic signaling (PTTG1IP) 
allowed to validate their role in senescent cell immortality, as the siRNA-mediated silencing of these 4 proteins 
led to cell death. 
 
The understanding of molecular mechanisms involved in cellular senescence, autophagy and apoptosis becomes 
increasingly important in aging and cancer research. Sufficient understanding how they regulate each other could 
provide novel therapeutic opportunities for the specific elimination of senescent skin fibroblasts. Current 
biological markers used to detect senescent cells in vitro and in vivo are limited and lack specificity. Thus, 
identification of novels senescent markers would have diagnostic and therapeutic potential. 
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2. Introduction 
 
 
2.1. Skin 
The human skin is a large and complex organ whose primary function is to protect the organism against external 
threats. This includes protection from bacteria, viruses and fungi, mechanical impacts and pressure, radiations, 
chemicals, temperature variations and dehydration1-5. The skin is also the place where physiological processes are 
regulated, such as body temperature (perspiration, hairs and vascular system) and vitamin D3 synthesis6,7. Finally, 
it is composed of mechano- and thermo-receptors, providing tactical and thermal sensitivity to the organism8,9. 
 
2.1.1. Structure, composition and functions of the skin 
The skin is divided into three distinct layers; the epidermis, the dermis and the hypodermis (or subcutaneous 
tissue)10. Outermost layer of the skin, the function of the epidermis is to form a barrier with the exterior 
environment, avoiding water loss and entry of potential pathogens11. The epidermis is mostly made of 
keratinocytes which differentiate from the basal lamina to the top, where terminally differentiated keratinocytes 
form the stratum corneum, melanocytes and immune cells [Fig. 1]. 
 
 
 
Figure 1: Structure and cell populations of the skin. The epidermis mostly comprises keratinocytes at various 
stages of differentiation, melanocytes and immunes cells, forming the barrier of the skin. Below the epidermis, 
the dermis has a relatively poor cell density and is mostly composed of fibroblasts and immune cells. The dermis 
is the layer where blood and lymphatic vessels are found, involved in nutrients supply and immune response. 
Highly abundant in the dermis, collagen and elastin fibers, involved in skin elasticity and turgor. The list of cell 
types is non-exhaustive. DETC: dendritic epidermal T cells, DC: dendritic cells, ILC: innate lymphoid cell and 
pDC: plasmacytoid dendritic cell. Figure from A. Pfalzgraff et al.12. 
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The dermis is a layer located deep to the epidermis and superficial to the hypodermis13. With a relatively low cell 
density, it is mainly composed of extracellular matrix (ECM), made of collagen and elastin fibers surrounded by 
glycoproteins, proteoglycans and glycosaminoglycans14. Fibroblasts are the most abundant cell type and are 
responsible for the synthesis of collagen and elastin fibers and ECM material, building a network of connective 
tissue which provides skin elasticity, turgor and mechanical resistance15. The dermis hosts blood & lymphatic 
vessels, hair follicles and sebaceous glands, supported in their respective function by macrophages, mast cells and 
adipocytes. Mast cells are inflammatory cells, involved in inflammatory response, wound healing and collagen 
remodeling16. Dermal adipocytes provide thermal protection, energy storage and are described to play a role in 
wound healing17. 
Also known as the subcutaneous layer, the hypodermis is the innermost and thickest layer of the skin. Made of 
a population of adipocytes, fibroblasts and macrophages, it is involved in fat storage and thermoregulation, 
hormone production and immune surveillance while providing attachment support for the upper layers to 
underlying tissues18. 
 
2.2. Skin aging and hallmarks of aging 
Because of its direct contact with the external environment, skin aging is impacted by internal and external factors 
which impairs cellular metabolism and induce structural and functional changes in the extracellular matrix. 
Intrinsic aging is an inevitable and genetically determined process partially due to free radical accumulation, 
hormonal shift and reduced cellular efficiency to repair internal damages. Other intrinsic factors, as oxidative 
stress, chronic inflammation and glycation have been shown to have a significant contribution to internal aging of 
the skin19. Upon natural aging, the population of fibroblasts and mast cells decreases in the dermis, reducing the 
production of collagen and elastin fibers. In parallel, the abundance of oligosaccharides decreases, limiting skin 
ability to bind and retain water. 
Extrinsic factors impacting the aging of the skin mostly depend on lifestyle and the environment, factors such as 
sun light, smoke, pollution and sleep. Skin exposition to UV radiations is the major extrinsic factor of aging and 
is responsible for about 80% of facial aging (referred as photoaging)20. 
Aging does not only involve skin, as a time-dependent progressive accumulation of damages and a loss of 
physiological integrity lead to an impairment of the function of many other organs and tissues. The accumulation 
of cellular damages overtime is considered as the main cause of aging and increases the risk factor of age-related 
pathologies such as cancer, diabetes and neurodegenerative diseases21-23. Intrinsic and extrinsic factors of aging 
induce cellular and molecular changes classified in 9 hallmarks of aging [Fig. 2]24. 
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Figure 2: Hallmarks of aging and their functional interconnections. The figure lists the 9 hallmarks of aging, 
classified in three groups: causes of damages (primary hallmarks), response to damages (antagonistic hallmarks) 
and response to the phenotypes (integrative hallmarks). Adapted from C. Lopez-Otín et al.24. 
 
 
2.2.1. Primary hallmarks of aging 
Genomic instability refers to the accumulation of unrepaired genetic damages upon aging25. Throughout lifetime, 
the integrity of the genetic material is constantly challenged by intrinsic factors (error in DNA replication, reactive 
oxygen species and viral-induced genome modifications) and extrinsic factors (chemical agents, pollution and 
UV), affecting nuclear and mitochondrial DNA26-28. 
During DNA replication, the ability of telomerase to completely replicate the end of the chromosomes (telomeres) 
is limited, leading to a loss in their integrity after each replication29. Sensed as DNA damage, this triggers a DNA 
Damage Response (DDR), involved in many aspects of aging30. 
Epigenetic alterations, including histone modifications, DNA methylation and chromatin remodeling play a role 
in organism longevity and aging31-33. 
Proteostasis englobes all biological pathways in the cell that mediate protein biogenesis, folding, trafficking and 
degradation34. Endogenous and exogenous cellular stresses cause the unfolding of proteins. Unfolded proteins are 
normally refolded by heat shock proteins (HSPs, which also control protein quality after translation)35, or targeted 
for degradation by the ubiquitin-proteasome system or by the lysosomal pathway (autophagy)34-37. Impaired 
protein proteostasis has been shown to play a role in aging and age-related pathologies34. 
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2.2.2. Antagonistic hallmark of aging 
The Insulin and IGF-1 signaling (IIS) pathway is an extraordinary conserved regulator of aging in evolution, 
influencing invertebrate and vertebrate longevity38,39. Downstream targets of the IIS include the FOXO proteins 
family and the mTOR complexes, both directly involved in aging processes40, and   mutations among members of 
the IIS have been linked to longevity41. 
Mitochondria are the organelles responsible for cellular energy production. As cell age, the efficiency of the 
respiratory chain (responsible for the production of ATP) decreases, while the production of ROS increases42. This 
phenomenon, known as the “free radical theory”, generates cellular damages. Contribution of dysfunctional 
mitochondria additionally occur through ROS-independent mechanisms, as deficient mitochondria are more 
sensitive to permeabilization and subsequent inflammation and/or apoptosis42. 
 
2.3. Cellular senescence, a hallmark of aging 
Skin fibroblasts have a finite lifespan in culture, known as the “Hayflick limit”. Observed for the first time by 
Leonard Hayflick in 1962, cells can divide approximatively 50-60 times before entering a non-proliferating state 
later known as cellular senescence43,44. Senescence is characterized by the irreversible cell cycle arrest and was 
first shown to be a consequence of the telomeres shortening, which occurs after each cell division (called 
replicative senescence)45-47. 
Not only restricted to telomeres shortening, senescence is triggered by various stresses, leading to stress- induced 
premature senescence (SIPS). These include oncogene hyperactivation (oncogene-induced senescence, OIS)48-50, 
oxidative stress51-53, mitochondrial dysfunction54,55, tumor suppression loss56,57, certain cytokines58,59 and other 
stresses inducing DNA/chromatin damages, such as UV, gamma irradiations and chemotherapeutic drugs60-63. 
 
2.3.1. Pathways involved in cellular senescence 
Molecular mechanisms underlying cellular senescence are complex and involve numerous pathways. The cell 
cycle arrest occurs mostly in the G1 phase and is mediated by the activation of the p16INK4a/Rb and/or the 
p53/p21CIP1 tumor suppressor pathways, which regulate cell cycle progression through cyclin-dependent kinase 
(CDK) inhibitors64-66 [Fig. 3]. 
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Figure 3: Stressors and pathways involved in cell cycle arrest. The senescence cell cycle arrest is mediated 
through two major pathways: p16INK4a/Rb and the p53/p21CIP1, which result in the repression of the Cyclin- 
Dependent Kinases 2, 4 & 6 (CDK4/6), the subsequent inhibition of retinoblastoma and of cell cycle. The DNA 
Damage Response (DDR) activates the p53 and the p16 pathways and is a common feature of almost all type of 
senescence. DDR-independent mechanisms also exist and converge in the p53 and p16 pathways. ROS: reactive 
oxygen species, CDK: cyclin-dependent kinase, DDR: DNA damage response. Figure adapted from Lujambio et 
al.67. 
 
 
The DNA Damage Response (DDR) is a network of cellular pathways involved in the detection and the repair 
of DNA damages through the regulation of the p53/p21CIP1 pathway. In the context of cellular senescence, the role 
of p53 varies according to the cellular stress; whereas persistent activation of DDR leads to cell cycle arrest 
through p53 activation, transient stress induces p53 to initiate a quiescence program and DNA repair process68. 
During senescence, exit from the cell cycle is often the consequence of a persistent DDR69, either caused by 
internal (telomeres shortening, oxidative stress) or external (UV, irradiation or chemotherapeutic drugs) stimuli. 
DNA damages and ROS (generated by OIS, dysfunctional mitochondria or senescence-associated secretory 
phenotype (SAPS)) activate p53 via the p38MAPK-ATM signaling pathway. Activated by the persistent DDR, 
the p53/p21CIP1 pathway drives the cell growth arrest through activation of the cyclin- dependent kinase inhibitor 
p21CIP1, which in turn blocks CDK2 activity and hypophosphorylates Rb70-72. In senescence, CDK inhibitors 
maintain Rb in a hypophosphorylated (active) form, which then inhibits E2F and promote senescence73. 
Accordingly, impairment of the p53/p21CIP1 pathway impairs the senescence program74, 
75. 
Persistent stress activates p16INK4a/Rb pathway, involved in the long-lasting arrest of the cell cycle through 
induction of INK4/ARF locus76. This locus, which encodes for CDKN2A, CDKN2B and p14ARF is repressed in 
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proliferating cells77. p14ARF is involved in the cell cycle arrest by stabilizing p53 via inhibition of HMDM2 
ubiquitin ligase. In senescent cells, CDKN2A (p16) is increased and contributes to the induction of premature 
senescence78, whereas CDKN2B (p15) is detected in SASP-mediated, DNA-damage, OIS- and developmentally 
programmed senescence79-81. It has been hypothesized that the p53/p21CIP1 pathway triggers the onset of 
senescence, whereas p16INK4a/Rb pathway maintains a durable cell cycle arrest82. 
 
2.3.2. The Senescence-Associated Secretory phenotype (SASP) 
Although blocked in G1 phase, senescent cells remain metabolically active and secrete a cocktail of growth factors, 
inflammatory cytokines, chemokines and matrix metalloproteases (MMP), called the senescence - associated 
secretory phenotype (SASP)83-86. Activation of the SASP is triggered by the DDR, via activation of NF- κB and 
C/EBP transcription factors and on the MAPK pathway87. 
The specific composition of the SASP depends on the cell type and the senescence inducer, which can have 
beneficial and detrimental effects on surrounding cells and tissue84 [Fig. 4]. 
 
 
 
 
Figure 4: Influence of the Senescence-Associated Secretory Phenotype (SASP) on surrounding cells and 
tissue. The SASP has both beneficial (green) and detrimental (red) effects. It accelerates would healing and plays 
a role in immune surveillance, favorizes tumor progression, induces senescence in nearby proliferating cells and 
promotes a chronic level of inflammation. Figure modified from N. Herranz et al.88. 
 
 
Through a positive gene expression feedback loop, the SASP reinforces itself in an intra-, auto- and paracrine 
manner89. Moreover, the SASP has been shown to induce senescence in nearby proliferating cells in a paracrine 
manner90,91. 
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While SASP-mediated induction of senescence in surrounding cells has a protective effect on tumor expansion, 
it also promotes malignant cell proliferation and vascularization increase, generating a pro-tumorigenic 
environment92,93. 
The role played by the SASP in the immune response is pleiotropic: The SASP stimulates the immune system and 
helps for the elimination of cancer and senescent cells94 and has immunosuppressive properties95. 
The SASP is linked to aging and age-related pathologies. The release of pro-inflammatory cytokines by senescent 
cells generates a low, chronic inflammation state referred as inflammaging96. Indeed, targeted elimination of 
senescence cells decreases the levels of proinflammatory cytokines and delays age-associated disorders97. 
 
2.3.3. Senescence and skin 
Senescent cells are reported apoptotic resistant98. Surprisingly, senescent fibroblasts upregulate pro-apoptotic 
initiators and downregulate the anti-apoptotic BCL-2 proteins, suggesting that the apoptotic program is initiated 
in senescent cells, but somehow restricted99. In the skin, senescent cells have been shown to accumulate upon aging 
in the dermis and epidermis100,101. In young tissue, the SASP adopted by senescent cells recruits macrophages and 
T cells, which target and eliminate senescent cells, allowing theclearance and the regeneration of the tissue. In 
aged tissues, ability of the immune system to target senescent cells decreases, leading to their accumulation102 
[Fig. 5]. 
 
 
 
Figure 5: Senescent cells accumulate in aged tissue. Upon exposure to extrinsic and/or intrinsic stresses, a cell 
can turn senescent. In young tissue, the SASP mediates the recruitment of macrophages, which target and eliminate 
senescent cells, allowing the clearance and regeneration of the tissue. In aged tissue, senescent cells accumulate, 
which leads to a state of chronic inflammation and fibrosis, impairing tissue function. Figure obtained  from  
Munoz-Espin  et  al.86,  reproduced  with  permission  and  used  under  the  conditions  of  Springer Nature (terms 
and conditions for copyright). 
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2.4. Markers of senescence 
Involved in aging, age-related pathologies and cancer, identification and targeting senescent cells has an important 
therapeutic potential. Although considerable progresses have been done, the molecular mechanisms underlying 
cellular senescence remains partially understood and lack specific markers. 
Senescent cells undergo profound structural changes, notably at the level of chromatin. During the development 
of senescence, chromatin condensates and form foci, known as senescence-associated heterochromatin foci 
(SAHF), which are visible under microscopy103. SAHF silences E2F-regulated genes and triggers p16INK4a/Rb and 
p53/p21CIP1 pathways104. 
As p16INK4a/Rb and p53/p21CIP1 are critical pathways of senescence, respective expression of p16, p21 and p53 are 
used as senescence markers105,106. In parallel, markers like p15, ARF, IL-6 and IL-8 (SASP component) may also 
be used107,108. 
The DNA damage response leads to the recruitment of several protein complexes, including the phosphorylated 
form of the histone H2AX (γH2AX) which forms foci at the lesion site. γH2AX foci increases in vitro and invivo 
during aging, making it a reliable senescence marker109. 
The current standard for the detection of senescent cells in vitro relies on the activity at pH 6.0 of a specific 
enzyme, the senescence-associated β-galactosidase (SA-β-Gal)110. The SA-β-Gal is a lysosomal enzyme which 
activity is thought to be a consequence of the enlargement of lysosomes observed in senescent cells, and might 
have no impact on senescence development nor maintenance111. The activity of the SA-β-Gal increases with aging 
in human skin100. Weather SA-β-Gal activity is a suitable marker for the identification of senescent cells remains 
debated for several reasons; First, high cell confluence and certain chemical treatments stimulates the SA-β-Gal 
activity112. Second, lysosomes are directly involved in the autophagic process, whose exact role is strongly debated 
in the context of senescence. This rends the activity of this enzyme in the context of senescence ambiguous and 
might lead to false positive results. 
Markers currently used to detect senescent cells are involved in several biological processes which are not per 
se linked to senescence. Thus, none of the one described above are reliable for the detection and the targeting of 
senescence, which urges for the identification of novels markers. 
 
2.5. Loss of proteostasis 
Accumulation of misfolded proteins upon aging has deleterious effects on cellular metabolism. Two major 
pathways are responsible for the elimination of these proteins: The ubiquitin-proteasome system (UPS) and 
autophagy. 
Autophagy is an evolutionary conserved mechanism maintaining cellular homeostasis through degradation and 
recycling of misfolded proteins and misfunctioning organelles. Not directly considered as a hallmark of aging 
perse, autophagytakespartwiththeubiquitin-proteasomesysteminthehallmark   “loss ofproteostasis”24. During life 
span, the efficiency of the autophagy-lysosome system and the ubiquitin-proteasome system declines, leading to 
theaccumulation of misfolded proteins (aggregates) and dysfunctional organelles, such as mitochondria 113,114 [Fig. 
6]. 
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Figure 6: Protein quality control systems. During and after translation, Heat Shock Proteins (HSPs) help with 
the formation of functional proteins by ensuring correct folding. With aging and stresses, misfolded proteins 
accumulate, impairing cellular functions. (1) The HSPs represent the first line of defense by refolding (Refo) 
misfolded proteins. (2) When HSPs are unable to refold proteins, chaperones proteins direct misfolded proteins 
for degradation via the Ubiquitin-Proteasome System (UPS). This requires previous poly- ubiquitination (pU) of 
the misfolded proteins, most commonly on lysine residue 48 (K48). The ubiquitinated protein is then recognized 
and degraded by the proteasome. (3) When HSP refolding and UPS are overloaded, misfolded proteins aggregate 
in the cytosol and are poly-ubiquitinated on lysine residue 63 (K63). K63 poly- ubiquitination induces degradation 
by autophagy (AP). This includes sequestration of protein aggregates in a double-membrane vesicle, called 
autophagosome, which subsequently fuses with lysosome. Lysosomal enzymes degrade autophagosome content. 
(4) HSPs are involved in protein quality control by targeting misfolded proteins for lysosomal degradation. This 
specific form of autophagy, called Chaperone-Mediated Autophagy (CMA), allows to degrade proteins in a very 
precise and selective way. Adapted from K-L. Lim et al.115. 
 
 
Autophagy occurs in different programs; microautophagy, chaperone-mediated autophagy (CMA) and 
macroautophagy (hereinafter referred to as autophagy) [Fig. 7], which all deliver cytoplasmic components to 
the lysosome116. Autophagy delivers cellular materials to the lysosome by first engulfing it in a double membrane 
structure (phagophore), which matures in a LC-3 containing vacuole (autophagosome). At the end of the 
maturation, the autophagosome fuse with the lysosome (forming an autolysosome) where its content is degraded 
and recycled. By contrast, CMA and microautophagy delivers their content directly to the lysosome. 
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Figure 7: Autophagic pathways. Autophagy occurs in 3 different programs. (a) Macroautophagy engulfs 
cytosolic cargo in double membrane vesicles called autophagosomes. After a maturation process, autophagosomes 
fuse with lysosomes where their content is degraded by lysosomal enzymes. Macroautophagy can be in bulk, 
when nutrients are limited, or selective. (b) Microautophagy entraps cytosolic cargo by lysosome membrane 
invagination. Microautophagy can be in bulk or selective (mediated by HSP HSC70). (c) Chaperone- mediated 
autophagy (CMA) degrades proteins bearing KFERQ motif by delivering them to lysosomes via HSPs (HSC70) 
and LAMP2A receptors. Figure from S. Kaushik et al.117, reproduced with permission and used under the 
conditions of Springer Nature (terms and conditions for copyright). 
 
 
First described as a non-selective degradative pathway activated by poor nutrient containing culture medium, 
it is now known that autophagy plays a rolein several pathologies including cancer, neurodegenerative diseases, 
immune response and aging 118,119. Autophagy is activated upon starvation or deprivation of growth factors to 
ensure the energy balance of the cell, or upon various stresses including low oxygen levels, high oxidative stress 
or exposition to cytotoxic agent120. 
Under normal condition (nutrient-rich environment), a basal level of autophagy ensures that protein aggregates, 
as well as damaged and redundant organelles are selectively eliminated. This selectivity requires the cell to 
distinguish between normal and abnormal content and is mediated by the binding on the target of ubiquitin, a 
small regulatory protein (called ubiquitination)121. 
Ubiquitin is involved in two degradation processes: (1) the ubiquitin-proteasome system (UPS) and (2) the 
selective autophagy system, both activated after accumulation of damages. What directs an ubiquitinated product 
to be degraded by the UPS or the autophagic machinery is not fully understood and seems the depend on how 
ubiquitinis attached toits substrate (mono vs polyubiquitination) and on which of the 7 lysine residues122. 
Increasing evidences suggest that the two processes are strongly interconnected123. However, whether they act 
independently or in accordance remains unclear. Upon proteasome dysfunction, a compensatory autophagic 
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pathway for the elimination of proteins aggregates has been shown to be settled by p62, suggesting that the UPS 
and autophagic machinery work together for the elimination of misfolded proteins124. 
 
2.5.1. Pathways involved in autophagy 
Autophagy is activated upon starvation or deprivation of growth factors to ensure the energy balance of the cell 
or upon various stresses including low oxygen levels, high oxidative stress or exposition to cytotoxic agent120. The 
autophagy machinery is regulated by several autophagy-related proteins (ATG) and is divided into 5 sequential 
steps: (1) initiation, (2) membrane nucleation and formation of the phagophore, (3) expansion, (4) fusion and (5) 
degradation [Fig. 8]. 
 
 
 
 
Figure 8: Schematic depiction of the macroautophagy process. mTOR and AMPK signaling are regulators 
of autophagy. Upon autophagy initiation, a double membrane forms and englobes the cytoplasmic component to 
be recycled (phagophore). Nucleation, maturation and expansion of the phagophore rely on the activity of the 
PI3KIII complex, ATG and LC3 proteins and leads to the formation of the autophagosome. Following 
autophagosome maturation, its fusion with lysosome (autolysosome) degrades its content by the activity of 
lysosomal hydrolases. Figure obtained from M. Hansen et al.125, reproduced with permission and used under the 
conditions of Springer Nature (terms and conditions for copyright). 
 
 
Autophagy is tightly regulated by two upstream regulators, AMPK and mTOR [Fig. 8]. mTOR comprises two 
distinct complexes, mTORC1 and mTORC2. The mammalian target of rapamycin complex 1 (mTORC1) is a 
master regulator of cell growth and metabolism126, whose activity is impaired upon cellular stress signals including 
amino acids starvation, growth factor deprivation, hypoxia and ROS accumulation. Inhibition of mTORC1 leads 
to ULK1 dephosphorylation, which subsequently activates the autophagy machinery127,128. Components of the 
mTORC1 are mTOR, rapamycin-associated protein of TOR (Raptor) and mLST8129. 
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Inhibition of mTORC2 activates autophagy through impaired inhibition of FoxO3, a transcription factor involved 
in the regulation of several autophagy-related genes130,131. The core components of the mTORC2 are mTOR, 
rapamycin-insensitive companion of TOR (Rictor), SIN1 and mLST8129. During starvation, adenosine mono-
phosphate-activated protein kinase (AMPK) senses decreases cellular ATP levels and activates autophagy directly 
through ULK1 phosphorylation. 
When the autophagic machinery is activated, the nucleation of the autophagosome membrane is regulated by the 
PI3K complex, including Atg5, Atg7 and Atg12. Maturation of the autophagosome include the binding of LC3 to 
the phagophore membrane, which is responsible for the specific recognition of cargo through the use of protein 
adaptor, such as p62. Mature autophagosome fuses with lysosomes, which induces the degradation of the 
autophagosome content. 
 
2.5.2. Carbohydrates as modulators of autophagy 
During aging, a decline in autophagic activity has been reported in a variety of tissues, and its 
genetic/pharmacological inhibition leads to premature aging132. Consistently, stimulation of autophagy delay 
aging and has beneficial effects on organism’s longevity132. In contrast, the increased autophagic activity observed 
in cancer cells contributes to their survival133. Therefore, context-dependent modulation of autophagy is the core 
of several therapeutic approaches for the treatment of aging and age-related pathologies. 
Carbohydrates, commonly termed “sugars”, are a large class of molecules consisting of carbon, hydrogen and 
oxygen. Carbohydrates are classified in four groups: (1) The monosaccharides, built of a single unit of 
carbohydrate with the chemical structure C6H12O6, such as glucose. (2) The disaccharides, made of two 
monosaccharides, such as trehalose. (3) The oligosaccharides, containing three to ten monosaccharides, such as 
raffinose. (4) The polysaccharides, polymers of long monosaccharides chains connected through glycosidic bonds, 
such as cellulose. Based on their capability to act as reducing agent, sugars are further classified into reducing and 
non-reducing sugars. Reducingsugarshaveafree aldehyde orketonegroup, abletocedean electron to oxidizing 
agents. Reducing sugars include all monosaccharides, along with some di-, oligo- and poly- saccharides. Non-
reducing sugars, such as sucrose, are carbohydrates that cannot be oxidized in aqueous solution, thus unable to 
generate aldehyde/ketone groups-containing compounds. 
Sugars gained attention for their potential ability to modulate autophagy. For instance, trehalose has been reported 
to increase autophagic activity, providing neuroprotection in Huntington disease and contracting prion 
infection134,135. First thought to modulate autophagy through regulation of mTOR activity, Chen et al. reported an 
mTOR-independent activation of autophagy by trehalose, sucrose and raffinose136. Although sugars are widely 
considered as autophagy inducers, recent report from Yoon et al. showed that trehalose could be in fact a potent 
inhibitor. 
Although the exact mechanisms by which carbohydrates modulate autophagy are poorly understood, their careful 
use as autophagy modulators may have beneficial effects in the context of aged-related pathologies. 
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2.6. Senescence and autophagy 
In the context of senescence, the role of autophagy remains poorly understood. Senescence and autophagy share 
similarities, as they both have cytoprotective and cytotoxic effects137,138. While autophagy promotes cell survival 
by ensuring proteins and organelles quality control, it is also involved in the apoptotic program139. Similarly, while 
senescence prevents the multiplication of damaged cells, its associated secretory phenotype (SASP) promotes 
inflammation and a favorizes a tumorigenic environment140. 
The role of autophagy in senescence is perceived as a “double edge sword”, as it can promote and prevent 
senescence [Fig. 9]. 
 
 
 
 
Figure 9: Pro- and anti-senescence role of autophagy. In the context of senescence, autophagy is a double- 
edge sword and has anti-senescence properties (1-5, left panel) and pro-senescence properties (6-9, right panel). 
(1-3) Autophagy mitigates stressors that cause cellular senescence, such as dysfunctional mitochondria & ROS, 
ER stress and protein aggregates. (4) Autophagy maintains lysosomal membrane integrity. (5) p62-dependent 
autophagy degrades GATA4, a main regulator of the SASP. (6) By dealing with the accumulation of cellular 
stresses in senescent cells that should normally lead to cell death, autophagy promotes senescent cell longevity. 
(7) Through the TASCC, autophagy provides required building blocks for the synthesis of SASP components. 
(8) Autophagy degrades Δ133p53α, which releases p53 and triggers cell cycle arrest. (9) Autophagy degrades 
nuclear lamin B, which induces senescence. Figure adapted from Kwon et al.141. 
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Under normal conditions, autophagy acts as an anti-senescence mechanism [Fig. 9, left panel]. Autophagy 
mitigates stressors that cause senescence, such as dysfunctional mitochondria and ROS, ER stress, misfolded 
proteins and protein aggregates. Autophagy also regulates lysosomal integrity, as permeable lysosomes are 
extensively ubiquitinated and targeted for autophagic degradation, preventing the onset of senescence142. Through 
ubiquitination and p62-mediated elimination of GATA4, autophagy inhibits the production of the SASP143. 
Autophagy can also act as a pro-senescence mechanism [Fig. 9, right panel]. Autophagy promotes senescent cell 
survival by modulating the accumulation of cellular damages that should normally trigger a death program in 
senescent cells. The SASP requires a constant production of different factors and it has been shown that autophagy 
sustains this production by recycling amino acids used in their production144. As a consequence of oncogene-
induced senescence, lysosomes and mTOR accumulate in a distinct cellular compartment, known as the “TOR-
autophagy spatial coupling compartment (TASCC)”. At the TASCC, autophagy recycles amino acids which in 
turn stimulate the production of IL-6 and IL-8 (2 components of the SASP)145. Horikawa et al. demonstrated that 
autophagy is involved in the ubiquitin-mediated degradation of Δ133p53α, a p53 isoform that inhibits p53 full-
length146. Subsequent activation of p53 full length drives the cell cycle arrest and triggers senescence. Study of 
Dou et al. highlighted the presence the presence in the nucleus of LC3B, a ubiquitin-like protein associated with 
autophagosomal membrane. LC3B interacts with nuclear component lamin B and drive its degradation via 
autophagy during oncogene-induced senescence147. 
Current hypothesis proposes that the pro- and anti-senescent role of autophagy depends on different factors148. 
More specifically, Kwon et al. recently proposed a toolkit for the understanding of the complex relationship 
between autophagy and senescence, based on (1) the type of autophagy (selective vs bulk), (2) the timing (early 
vs late autophagy) and (3) the location (lamina degradation (nucleus) vs SAPS production (TASCC))141. 
Whether autophagy triggers and/or sustains a senescence phenotype in senescent  skin fibroblasts remains 
poorly understood and could lead to therapeutic approaches for the elimination of senescent cells. 
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3. Aims of the study 
 
 
Aging is accompanied by multiple cellular changes which alter organ homeostasis and function, promoting the 
onset of various aged-related pathologies. During lifespan, cells are exposed to various intrinsic and extrinsic 
stresses which trigger the senescence program. Apoptosis-resistant, senescent fibroblasts accumulate in the skin, 
where they promote a chronic inflammation state, favorize a tumorigenic environment and impact its overall 
appearance. 
Current markers allowing the identification of senescent cells are ambiguous and lack specificity. Thus, the 
identification of novel targets for the removal of senescent cells are of therapeutic interest in the context of aging 
and age-related pathologies. 
Autophagy is a degradative mechanism involved in organism longevity, whose function decreases upon aging. 
Although the implication of autophagy in the context of senescence is not questioned, their exact relationship 
remains poorly understood and debated. 
 
 
Thus, the aims of this work were as follows: 
 
 
• Analyze and compare the proteome of senescent and proliferating skin fibroblasts 
• Identify novel and relevant markers of senescence in skin fibroblasts 
• Evaluate the role of these markers in senescent skin fibroblasts viability 
• Understand the role of autophagy in the initiation, development and sustainability of doxorubicin- 
induced premature senescence in skin fibroblasts 
• Evaluate autophagy as a target for the elimination of senescent cells 
• Evaluate the ability of different carbohydrates to modulate autophagy in human skin fibroblasts 
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4. Materials and Methods 
 
 
4.1. Cell culture 
Juvenile foreskin fibroblasts (NHDF) were cultured in corresponding fibroblast growth medium (both PromoCell, 
Germany). WS1 fibroblasts (ATCC® CRL-1502TM, Germany) were cultured in Minimum Essential Medium 
(gibco® by Life Technologies™, ThermoFisher Scientific, USA) supplemented with 10 % fetal bovine serum 
(Biochrom GmbH, Merck KGaA, Germany) and 1 % UltraGlutamine™ I (Lonza, Belgium). All cells were cultured 
under standard cell culture conditions (37°C and 5 % CO2). 
 
4.2. Induction of premature senescence 
Senescence was induced in WS1 and NHDF using 0.5 µM doxorubicin (Sigma-Aldrich, USA) in corresponding 
culture medium for 24 hours, under standard cell culture conditions (37°C and 5 % CO2). After doxorubicin 
treatment, cells were washed 3 times in phosphate-buffered saline (PBS) (VWR, Germany) and allowed to recover 
for 14 days in corresponding culture media and under standard cell culture conditions (37°C and 5 % CO2). 
Senescence was induced when cell reached 70% confluency. Despite Doxorubicin treatment, it happened that 
fibroblasts were still proliferating 48 hours after the treatment. In this case, a second treatment with 0.3 
µM doxorubicin for 24 hours was applied. 
 
 
4.3. Detection of cellular senescence 
4.3.1. Cellular senescence activity assay 
NHDF and WS1 were cultured in 96-well plates (VWR, Germany) and treated with doxorubicin as previously 
explained. Senescence was assessed in doxorubicin-treated WS1 and NHDF using the Cellular Senescence 
Activity Assay (SA-β-gal Activity, Fluorometric Format) (ENZO, USA). Briefly, culture medium was removed, 
and cell were washed 1x with 200 µL/well cold PBS (VWR, Germany). Cells were further lysed with 100 µL/well 
cold lysis buffer and incubated for 5 minutes at 4oC. Whole cell lysates were transferred to microcentrifuge tubes 
and centrifuged for 10 minutes at 4oC. Supernatants were collected and protein concentration determined by 
Bradford assay (see below). 50 μL of lysates at a concentration of 50 mg/mL were used in triplicate in another 
96-well plate. Lysates were incubated with 50 μL freshly prepared 2x Assay Buffer for 2.5 hours at 37 °C (w/o 
CO2), protected from light. 50 μL of the reaction mixture were removed, and 200 μL stop solution added. 
Fluorescence intensity was detected using a Spark® 20M multiplate reader (TECAN, Switzerland). Excitation 
360 nm, Emission 465 nm. 
 
4.3.2. SA-β-Gal staining 
NHDF and WS1 were cultured in 6-well plates (VWR, Germany) and treated with doxorubicin as previously 
explained. Senescence was assessed in WS1 and NHDF using a senescence β-galactosidase staining kit (Cell 
Signaling, Germany). Briefly, culture medium was removed, and cell were washed 1x with 2 mL/well cold PBS. 
Cells were further fixed at room temperature with 1mL 1X fixative solution (Cell Signaling, Germany). After 
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15 minutes, cells were washed 3x with 2 mL/well cold PBS. Cells were further stained with 930 µL/well staining 
solution (equilibrated at pH 6) for 12 hours at 37 °C (w/o CO2). Staining solution was removed, cells were washed 
3x in cold PBS and 500 µL/well culture medium added. Imaging was performed with a Primovert light microscope 
using an Axiocam 105 color (Carl Zeiss Microscopy GmbH, Germany). 
 
4.4. Protein concentration 
Protein concentration was determined using the Quick Start™ Bradford protein assay (Bio-Rad, USA). Briefly, 
cells were washed 1x in cold PBS and lysed on ice for 15 minutes in CellLytic M (Sigma Aldrich, USA) containing 
protease inhibitor cocktail cOmplete Mini and phosphatase inhibitor PhosSTOP (both from Roche Diagnostic 
GmbH, Germany). Subsequently, cell lysates were stocked at -80oC four 1 hour. Prior to Bradford assay, cell 
lysates were centrifuged at 1300G for 3 minutes and supernatant collected for Bradford assay. Bradford assay was 
performed according to manufacturer´s protocol. 
 
4.5. Samples preparation for 2D-LC-MS/MS analysis 
For each condition (proliferating and senescent), 3 donors of Normal human Dermal Fibroblast (NHDF) were 
used. NHDF were harvested, homogenized and lysed using Cell Lytic M and protease/phosphatase inhibitors 
(Roche). Subsequently, total protein amount was measured with the Pierce™ Rapid Gold BCA Protein Assay Kit 
(Thermo Fisher, Germany). Cells were lysed as previously explained. 10 µg of each sample were reduced, 
alkylated, digested and purified using EasyPrep Mini MS sample Prep Kit (Thermo Fisher, Germany). After a 
drying step, samples were resuspended in 100 mM TEAB solution and labeled with TMT6plex™ Isobaric Label 
Reagent Set according to manufacturer’s protocol (Thermo Fisher, Germany). Finally, samples were merged and 
cleaned up using Pierce™ Peptide Desalting Spin Columns (Thermo Fisher, Germany). 
 
4.6. 2D-LC-MS/MS analysis 
Mass spectrometry analysis of proteome was carried out using 2D-LC-MS/MS system and a TMT6plex label 
quantification approach. Mixture containing 3 biological replicates for each condition (normal and senescent) 
were first separated sequentially using multidimensional chromatographic techniques. The first eight fractions 
were generated by the ion-exchange chromatography and were further separated by reversed-phase 
chromatography. MS/MS analysis was performed using a and a Q-Exactive™ Hybrid QuadrupoleOrbitrap™ mass 
spectrometer (ThermoFisher) equipped with a nano-electrospray ion source. LC-MS/MS analysis was performed 
in 2 technical replicates. 
 
4.7. Protein identification and quantification 
Proteins were identified and quantified using Proteome Discoverer search engine (version 2.3.0.523). MS/MS 
spectra were searched against the UniProtKB database (06.05.2019). Search parameters were as follows: 
Enzyme Name: Trypsin / Max. Missed Cleavage Sites: 3 / Precursor Mass Tolerance: 12ppm / Fragment 
Masse Tolerance: 0.04Da / Dynamic Modifications: Carbamidomethyl (+57.021Da, C), TMT6plex 
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(+229.163Da, K), Oxidation (+15.995Da, M), phosphorylation (+79.996Da, C,S,T and Y) and deamination 
(+0.984Da, N, Q and R). The false discovery rate was set to 1% (p ≤ 0.01). A minimum of 2 unique peptides were 
required and only proteins found in all samples were retained for quantification. Then, protein abundance was 
compared across samples by taking the protein abundance ratio senescent/proliferating. 
 
4.8. Gene set enrichment analysis 
Functional enrichment analysis was performed using g:Profiler (version e98_eg45_p14_ce5b097), mining Gene 
Ontology Biological Processes (GO:BP) and Reactome (REAC) databases. Multiple testing correction was 
performed using Benjamini-Hochberg FDR multiple testing correction method with a significance threshold set 
to 0.05. To avoid limited interpretative value of large pathways and statistical power decrease due to small 
pathways, the size of functional category was set between 5 (min) and 350 (max) genes, as previously described 
(J. Reimand et al., Nature protocols 2019). Resulting enrichment analysis data were exported in Cytoscape 
(version 3.7.1) and visualized using EnrichmentMap application with a node cutoff Q-value of 0.04 and an edge 
cutoff (similarity) of 0.5. Nodes were manually grouped into cluster of similar biological functions. 
 
4.9. Modulation of autophagy 
4.9.1. Chemicals-mediated modulation of autophagy 
To stimulated autophagy, WS1 and NHDF were treated with 0.5 µM rapamycin (Novex® by Life Technologies™, 
ThermoFisher Scientific, USA) for 24 hours in corresponding culture media and under standard cell culture 
conditions (37°C and 5 % CO2). After rapamycin treatment, cells were washed 1x in cold PBS. To inhibit 
autophagy, WS1 and NHDF were treated with 10 µM chloroquine (provided in CYTO-ID® Autophagy Detection 
Kit 2.0, Enzo, USA), or 16.5 µM wortmannin (InvivoGen, Germany) for 24 hours in corresponding culture media 
and under standard cell culture conditions (37°C and 5 % CO2). After treatment, cells were washed 1x in cold PBS 
and cultured under standard cell culture conditions (37°C and 5 % CO2). 
 
4.9.2. siRNA-mediated inhibition of autophagy 
Autophagy was inhibited in NHDF using siRNA. All siRNA (Silencer® Select) were purchased from 
ThermoFisher. Scramble siRNA (cat. no. 4390844), siRNA targeting GAPDH (cat. no. 4390850), Atg5 (cat. no. 
4393421), and Atg7 (cat. no. 4393420), were used at a concentration of 20 nM in culture medium for 72 hours, 
and under standard cell culture conditions (37°C and 5 % CO2). Briefly, 104 NHDF/well were seeded in a 96- well 
plate. The next day, NHDF were transfected with 20 nM siRNA using Lipofectamine® 3000 reagent (Thermo 
Fisher, Germany), according to manufacturer’s protocol. 
 
4.9.3. Carbohydrates-mediated inhibition of autophagy 
Autophagy was modulated in NHDF using different carbohydrates (sugars). Glucose, maltose, sorbitol, raffinose, 
trehalose, sucrose, methyl-α-glucopyranoside and gluconic acid (all from Sigma-Aldrich, USA) were used at a 
concentration of 50, 100 and 200 mM in culture medium for 24 hours. Isomaltulose (USP, USA) and 
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meglumine (Merck KGaA, Germany) were used at a concentration of 50, 100 and 200 mM for 24 hours. After 
treatment, cells were washed 1x in cold PBS and cultured under standard cell culture conditions (37°C and 5 % 
CO2). 
 
4.10. Detection of autophagic activity 
The level of autophagic vesicles in WS1 fibroblasts at a given timepoint was assessed using the CYTO-ID® 
Autophagy Detection Kit 2.0 (Enzo, USA) according to the manufacturer’s instructions for fluorescence 
microplate applications. Briefly, WS1 were seeded at a density of 104 cell/well in a 96-well plate. After modulation 
of autophagy, cells were washed 1x in 100 µL/well 1X assay buffer. Right after, 100 µL microplate dual detection 
reagents were added to each well for an incubation time of 60 minutes (instead of 30) at 37oC, protected from 
light. Cells were further washed twice with 200 µL/well assay buffer and 100 µL/well of assay buffer added to 
each well. Fluorescence intensities were detected using a Spark® 20M multiplate reader (TECAN, Switzerland) 
(CYTO-ID® Excitation 485 nm, Emission 535 nm. Hoechst 33342 Excitation 320 nm, Emission 465 nm). 
 
4.11. Western Blot analysis 
Protein extracts were obtained by lysing WS1 fibroblasts in CellLytic M (Sigma-Aldrich, USA) complemented 
with protease inhibitor cOmplete Mini and phosphatase inhibitor PhosSTOP (Roche Diagnostics, Germany) for 
15 minutes on ice, and subsequently frozen 1 hour at -80oC. Total protein concentration was determined by 
Bradford assay (Bio-Rad, USA). Indicated protein amounts were separated on 8-16% Midi Criterion™ TGX 
Stain-Free™ precast polyacrylamide gels (LC3) or on 4-15% Midi Criterion™ TGX Stain-Free™ precast 
polyacrylamide gels (all other target) (Bio-Rad, USA) at 100 Volts. Proteins were transferred onto PVDF 
membranes (Bio-Rad, USA) using Trans-Blot® Turbo™ Transfer System (Bio-Rad, USA) at 2.4 A and 25 V for 
7 minutes. Membranes were blocked in TBS (Bio-Rad, USA) supplemented with 5% Tween20 (Merck, Germany) 
and 5% BSA (Sigma-Aldrich, USA) for 1 hour at RT. Membranes were incubated with primary antibodies (anti-
LC3A/B (D3U4C) XP®, anti-ß-actin (D6A8), anti mTOR (7C10), anti-Phospho-mTOR (Ser2481), anti-Rictor 
(53A2), anti-Phospho-Rictor (Thr1135) (D30A3), anti-Raptor (24C12), anti-Phospho- Raptor (Ser792), all from 
Cell Signaling Technology, (USA) diluted 1:1000 in 5 % BSA in TBS-T (0.1 %). Anti- APOL2 (rabbit polyclonal, 
ab196771, Abcam) was diluted 1:1000, anti-CES2 (rabbit polyclonal, ab126970, Abcam) was diluted 1:1000, 
anti-MGARP (mouse monoclonal, MA5-27537, Thermo Fisher) was diluted 1:2000 and anti-PTTG1IP (mouse 
polyclonal, ab68208, Abcam) was diluted 1:500 in 5% BSA in TBS-T (o.1%). Prior to secondary antibody 
incubation, membranes were washed 3 times in TBS-T (0.1%) for 5 min. Membranes were incubated with 
secondary antibody (anti-rabbit-IgG, HRP-conjugated, Cell Signaling, USA) diluted 1:2000 in TBS-T (0.1%) and 
5% BSA at RT for 2 hours. Protein bands were visualized by adding AceGlowTM chemiluminescence substrate 
solutions A and B (1:1) (VWR International, USA) and chemiluminescence was captured with the imaging system 
Fusion FX (Vilber Lourmat, Germany). Band intensities were quantified with the BIO-1D software, version 15.07 
(Vilber Lourmat, Germany). ß-actin served as a loading control. 
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4.12. siRNA-mediated gene silencing 
siRNA targeting APOL2, CES2, PTTG1IP and MGARP protein (all ThermoFisher, Germany, cat. no. 4392429) 
were used at a concentration of 5 mM according to manufacturer´s protocol. NHDF were seeded in 96-well plates 
at a concentration of 10´000 cells/well. The next day, NHDF were treated with corresponding siRNA every 72 
hours according to manufacturer´s protocol, as previously explained. Scramble siRNA (cat. no. 4390844), siRNA 
targeting GAPDH (cat. no. 4390850), transfection reagent (Lipofectamine 3000) and “untreated cells” served as 
controls. 
 
4.13. ATP assay 
Cytotoxic effect of autophagy modulation in senescent WS1 fibroblasts and 4 candidates silencing in NHDF was 
monitored using the ATPlite™ 1step Luminescence Assay System (PerkinElmer, USA) according to 
manufacturer’s protocol. Briefly, cells were cultured in 96-well plates under standard cell culture conditions (37°C 
and 5 % CO2). After treatment (siRNA, autophagy modulators and carbohydrates), 100 µL/well culture medium 
were removed and refiled with 100 µL/well reconstituted reaction reagent (provided in the kit). Plates were 
subsequently shacked for 5 minutes at 700 rpm and at room temperature, protected from light, using an orbital 
microplate shaker, with an orbit diameter of 3 mm. Luminescence was detected using a Spark® 20M multiplate 
reader (TECAN, Switzerland). Untreated cells served as negative control. Cells treated with 7.5% Tween80 (G 
Biosciences, USA) as positive control. 
 
4.14. Electron microscopy 
Normal human dermal fibroblasts were induced senescent using doxorubicin, as previously explained. After 2 
weeks of recovery time, NHDF were cryo-fixed within a few milliseconds at a pressure of 200 bar using a high- 
pressure freezer Compact 1 (Wohlwend GmbH, Switzerland). Freez-substitution was conducted using a Leica EM 
AFS 2 device (Leica Microsystems, Germany). Here, the substitution / staining medium (acetone p.a., 0.2% 
osmium tetroxide, 0.1% uranylacetate and 5% water) was pre-cooled to -90 °C before samples were added. 
Finally, the samples were embedded in EPON 812 and sectioned at room temperature using a diamond knife. 
Examination of the thin sections was conducted with a FEI Tecnai F20 transmission electron microscope (FEI, 
USA) operated at an acceleration voltage of 200 kV. Conventional bright field images were acquired using a 
Gatan US1000 slow scan CCD camera (Gatan Inc., USA). 
 
4.15. Statistical analysis 
All experiments were conducted with at least 3 technical replicates. Statistical analysis was performed using 
GraphPad Prism 7 (GraphPad Software, USA). One-way ANOVA followed by Tukey’s multiple comparison test 
was performed for treatments individually or whole data sets as indicated. α = 0.05. Significances (****): p 
< 0.0001, (***): p < 0.001, (**): p < 0.01, (*): p < 0.05, (ns): p ≥ 0.05. 
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5. Results 
 
 
5.1. Induction and monitoring of cellular senescence in WS1 fibroblasts 
Premature senescence was induced using doxorubicin (Dox) in WS1 fibroblasts. To assess whether Dox- treatment 
induced senescence, two methods based on the activity of the Senescence-Associated beta- galactosidase (SA-β-
gal), known as a biomarker of cellular senescence, were used. First, SA-β-gal activity was measured in cell lysates 
using a fluorometric substrate. Second, fixed cells were provided a modified galactosidase substrate (X-gal), 
metabolized upon enzyme activity and detectable by light microscopy as blue precipitate. 
 
5.1.1. SA-β-gal activity is increased in senescent WS1 fibroblasts 
WS1 fibroblasts were treated with 0.5 µM Dox for 24 hours to induce premature senescence and allowed to 
recover for 14 days. After 14 days, SA-β-gal activity from Dox-treated (SC) cells was compared to untreated (UT) 
(see sections 4.2 and 4.4). The fluorescence signal was significantly 2.6-fold increased in SC compared to UT 
WS1, indicating higher SA-β-gal activity and development of senescence [Fig. 10a]. To confirm senescence in 
Dox-treated WS1 fibroblasts, untreated- and Dox-treated cells were fixed and stained for SA-β-gal activity. Dox-
treated WS1 showed strong staining [Fig. 10b, right] compared to untreated WS1 [Fig. 10b, left]. 
 
 
 
Figure 10: Cellular senescence activity assay in WS1 fibroblasts. SIPS was induced in NHDF using 
doxorubicin. After 14 days of recovery time, SA-β-gal activity was measured. (A) SA-β-gal activity of lysate 
from Dox-treated cells (SC) was compared to untreated (UT). Values obtained from 3 biological replicates, each 
in 3 technical replicates and expressed in Relative Fluorescent Unit (RFU). Means ± SEM are shown. Means 
compared using unpaired t-test: (****): <0.0001. (B) SA-β-gal staining. Blue staining indicates senescent cells 
(red arrows). Scalebar: 100 µM. 
 
 
5.2. Differential proteome analysis of senescent NHDF by 2D-LC-MS/MS labeling-assisted 
proteomics 
Molecular mechanisms underlying cellular senescence remain poorly understood. The proteome of senescent skin 
fibroblasts was analyzed by 2D-LC-MS/MS labeling-assisted proteomics. 
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Stress-induced premature senescence (SIPS) was triggered in normal human dermal fibroblasts (NHDF) using 
doxorubicin (Dox). As previously described, Dox-treated cells require a few days to recover and develop a 
senescent phenotype149. 14 days after SIPS induction, senescence phenotype was assessed by SA-β-gal staining 
[Fig. 11] and subsequent differential proteome analysis was conducted by 2D-LC MS/MS labeling-assisted 
proteomics (see sections 4.6 to 4.8). 
 
 
 
Figure 11: SA-β-gal staining of Normal Human Dermal Fibroblasts. SIPS was induced in NHDF using 
doxorubicin. After 14 days of recovery time, cells were stained for SA-β-gal activity. Blue staining indicates 
senescent cells. Scale bar: 100 µM. 
 
 
A total of 4147 proteins were identified at a 1% false discovery rate (FDR), among which 20 proteins were specific 
to proliferating NHDF and 19 to senescent NHDF [Table 1a and 1b, respectively]. 
 
 
 
Accession Description Gene Symbol 
Q9Y5Q8 General transcription factor 3C polypeptide 5 GTF3C5 
P58044 Isopentenyl-diphosphate Delta-isomerase 1 IDI1 
O00221 NF-kappa-B inhibitor epsilon NFKBIE 
Q3SWX9 Double-strand-break repair protein rad21 homolog RAD21 
O15254 Peroxisomal acyl-coenzyme A oxidase 3 ACOX3 
Q13356 RING-type E3 ubiquitin-protein ligase PPIL2 PPIL2 
Q5R746 3'-5' RNA helicase YTHDC2 YTHDC2 
Q9Y6G3 39S ribosomal protein L42, mitochondrial MRPL42 
P41742 Tubulin beta chain TUB2 
Q9GL73 Zinc phosphodiesterase ELAC protein 2 ELAC2 
Q68D10 Protein SPT2 homolog SPTY2D1 
Q53GL7 Protein mono-ADP-ribosyltransferase PARP10 PARP10 
Q96PZ2 Protein FAM111A FAM111A 
Q9N0Y0 Vesicle-associated membrane protein 2 VAMP2 
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Q4R588 Hsp70-binding protein 1 HSPBP1 
Q91WK7 Ankyrin repeat domain-containing protein 54 Ankrd54 
Q86YV9 Hermansky-Pudlak syndrome 6 protein HPS6 
P24386 Rab proteins geranylgeranyltransferase component A 1 CHM 
Q8TEB9 Rhomboid-related protein 4 RHBDD1 
O95365 Zinc finger and BTB domain-containing protein 7A ZBTB7A 
Table 1a: Proteins specific to proliferating NHDF as identified by 2D-LC MS/MS labeling-assisted 
proteomics. Differential proteome analysisby 2D-LC-MS/MSidentified 20 proteinsonlyfoundin proliferating 
NHDF. 
 
 
 
Accession Description Symbol 
O95210 Starch-binding domain-containing protein 1 STBD1 
P55288 Cadherin-11 CDH11 
Q71U07 Thrombomodulin THBD 
P82930 28S ribosomal protein S34, mitochondrial MRPS34 
Q6PCT5 Polyglutamine-binding protein 1 PQBP1 
Q04690 Neurofibromin NF1 
O75420 GRB10-interacting GYF protein 1 GIGYF1 
Q15283 Ras GTPase-activating protein 2 RASA2 
O95396 Adenylyltransferase and sulfurtransferase MOCS3 MOCS3 
Q16611 Bcl-2 homologous antagonist/killer BAK1 
Q9L6W9 S-adenosylmethionine tRNA ribosyltransferase-isomerase QUEA 
Q5R801 5'-AMP-activated protein kinase subunit beta-1 PRKAB1 
Q60592 Microtubule-associated serine/threonine-protein kinase 2 MAST2 
Q5HYI8 Rab-like protein 3 RABL3 
P25311 Zinc-alpha-2-glycoprotein AZGP1 
Q9NZQ3 NCK-interacting protein with SH3 domain NCKIPSD 
Q96LJ7 Dehydrogenase/reductase SDR family member 1 DHRS1 
Q96B49 Mitochondrial import receptor subunit TOM6 homolog TOMM6 
O75427 Leucine-rich repeat and calponin homology domain-containing protein 4 LRCH4 
Table 1b: Proteins specific to senescent NHDF as identified by 2D-LC MS/MS labeling-assisted 
proteomics. Differential proteome analysis by 2D-LC-MS/MS identified 19 proteins only found in senescent 
NHDF. 
 
 
If not otherwise specified, only proteins with at least two unique peptides were selected for further analysis. 
Among the 4´147 proteins, 2´642 proteins respected this latest criterion. To identify differentially expressed 
proteins (DEPs) in senescent NHDF, means S/P abundance of each protein were displayed in a volcano plot 
[Fig. 12]. With a threshold set at ±1.5-fold change, 230 and 228 proteins were found to be significantly up- and 
down-regulated in senescent NHDF, respectively. 
34 
 
 
 
 
Figure 12: Differentially expressed proteins in senescent normal human dermal fibroblasts. For each protein 
detected by 2D-LC-MS/MS, the mean abundance ratio “senescence/proliferating” of each detected proteins (log2) 
was plotted against its corresponding p-value (-log10). P-values were calculated from 3 biological replicates (n=3). 
Proteins with at least ±1.5 fold changed expression are displayed in green (downregulated, 228) and red 
(upregulated, 230). 
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5.3. Gene set enrichment analysis 
A gene set enrichment analysis (GSEA) is a method to identify biological pathways that are enriched in a genes 
list, more than what would be expected by chance150. To have an insight of biological pathways impaired in 
senescent NHDF, down- and up-regulated proteins were separately subjected to a GSEA, mining Gene Ontology: 
Biological process (GO:BP) and Reactome (REAC) databases. 
 
5.3.1. GSEA of downregulated proteins 
GSEA of the 228 downregulated proteins was conducted using g:Profiler webtool. Mining Gene Ontology: 
Biological Process (GO:BP) and Reactome (REAC) databases, 532 GO:BP biological processes (BPs) and 149 
REAC pathways were found significantly enriched due to downregulated proteins in senescent NHDF [Fig. 13]. 
 
 
 
Figure 13: Downregulated proteins enrichment analysis. Proteins found to be downregulated in senescent 
NHDF were subjected to a gene set enrichment analysis, mining two databases: (1) Gene Ontology: Biological 
Process (GO:BP) and (2) Reactome (REAC). Each dot on the graph represent a biological process or a pathway. 
X-axis: mining GO:BP database, 532 biological processes were identified (orange). Mining REAC, 149 pathways 
were identified (blue). Y-axis: Adjusted p-values associated with each biological process and pathway. 
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To visualize the GSEA, impaired BPs and pathways were further mapped using Cytoscape software and 
manually grouped into clusters of similar functions as previously described150 (see section 4.9) [Fig. 14]. 
 
 
 
 
 
Figure 14: Enrichment map of downregulated proteins GSEA. All BPs and pathways enriched in senescent 
NHDF due to downregulated proteins were mapped and manually arranged according to function similarities. 
Each node (circle) represents a distinct biological process (GO:BP) or pathway (REAC), involving between 5 and 
520 genes. Color gradient describes the statistic linked to the identification of the biological processes and 
pathways. Edges (blue lines) represent the number of genes overlapping between two biological processes or 
pathways, determined using the similarity coefficient. Numbers (1-5) represent clusters of similar biological 
processes or pathway. (1) BPs involved in DNA repair, (2) BPs involved in DNA replication, (3) BPs involved 
in telomere maintenance, (4) BPs involved translation initiation and (5) BPs involved in nucleus organization. 
 
 
Visualization and grouping of the GSEA data identified BPs expected to be impaired in senescent cells, including 
BPs involved in DNA repair, DNA replication, telomere maintenance, initiation of translation and nucleus 
organization [numbered 1-5 on fig. 14 and table 2]. 
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No. Database Accession Description FDR q-value 
1 REAC REAC:R-HSA-73894 DNA repair 1.69E-02 
2 GO:BP GO:0033260 Nuclear DNA replication 3.43E-02 
3 GO:BP GO:0007004 Telomere maintenance 1.91E-02 
4 GO:BP GO:0006413 Translation initiation 5.00E-8 
5 REAC REAC:R-HSA-2995410 Nuclear envelope reassembly 2.89E-02 
Table 2: List of BPs and pathways known to be impaired in senescent cells. Table lists BPs and pathways 
identified on figure 4 with corresponding database, accession number and FDR q-value. 
 
 
Along with expected BPs, GSEA of downregulated proteins identified 34 BPs and pathways directly involved 
in viral defense and 53 involved in immune response, together counting for 13% of all enriched BPs in senescent 
NHDF [Appendix 1a and 1b, p. 103]. 
 
5.3.2. GSEA of upregulated proteins identified enriched autophagy-related processes in 
senescent NHDF 
 
Mining GO:BP and REAC, gene set enrichment analysis of the 230 upregulated proteins identified 490 Gene 
Ontology biological processes and 32 Reactome pathways to be significantly enriched in senescent NHDF [Fig. 
15]. 
 
 
 
Figure 15: Upregulated proteins enrichment analysis. Proteins found to be upregulated in senescent NHDF 
were subjected to a gene set enrichment analysis mining two databases: (1) Gene Ontology: Biological Process 
(GO:BP) and (2) Reactome (REAC). Each dot on the graph represent a biological process or a pathway. X-axis: 
mining GO:BP database, 280 biological processes were identified (orange). Mining REAC, 32 pathways were 
identified (blue). Y-axis: Adjusted p-values associated with each biological process and pathway. 
 
 
To visualize the GSEA of upregulated proteins, impaired BPs and pathways were further mapped and manually 
grouped into clusters of similar functions [Fig. 16]. 
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Figure 16: Enrichment map of upregulated proteins GSEA. All BPs and pathways enriched in senescent 
NHDF due to upregulated proteins were mapped and manually arranged according to function similarities. Each 
node (circle) represents a distinct biological process (GO:BP) or pathway (REAC), involving between 5 and 520 
genes. Color gradient describes the statistic linked to the identification of the biological processes and pathways. 
Edges (blue lines) represent the number of genes overlapping between two biological processes or pathways, 
determined using the similarity coefficient. Numbers (1-5) represent clusters of similar biological processes or 
pathway. (1) BPs involved in viral life cycle, (2) BPs involved in extracellular matrix organization, 
(3) BPs involved in cell cycle arrest, (4) BPs involved in apoptotic signaling and (5) BPs involved in lipid 
metabolism. 
 
 
Visualization and grouping of the GSEA data identified numerous BPs among which (1) viral life cycle 
(GO:0019058, FDR q-value =1.37E-5), (2) Extracellular matrix organization (GO:0030198, FDR q-value 
=3.80E-5), (3) cell cycle arrest (GO:0007050, FDR q-value =0.009), (4) apoptotic signaling (GO:2001233, FDR 
q-value =0.0285), and (5) lipid metabolism (GO:0006643, FDR q-value =1.01E-5), numbered 1-5 on Fig. 16. 
GSEA also identified 9 clusters on BPs (38) directly or indirectly   related to autophagy   [Fig. 17], accounting for 
8% of all enriched BPs in senescent NHDF, among which lysosome organization (GO:0007040, FDR q- 
value=1.37x10-5), regulation of macroautophagy (GO:0016241, FDR q-value=1.28x10-3), lysosomal transport 
(GO:0007041, FDR q-value=1.47x10-3) and regulation of mTOR signaling (GO:0032006, FDR q- value=3.09x10-
2). 
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Figure 17: Enrichment map of upregulated proteins GSEA – Magnification of autophagy-related clusters. 
GSEA identified 9 clusters of biological processes directly or indirectly related to autophagy, accounting for 8% 
of all enriched biological processes in senescent NHDF. 
 
 
5.4. Rapamycin and chloroquine modulate autophagy in WS1 fibroblasts 
The mTOR inhibitor Rapamycin (Rap) was used as autophagy activator. With its ability to block the fusion 
lysosomes-autophagosomes, Chloroquine (Cq) was used as autophagy inhibitor. Wortmannin and siRNA 
targeting Atg5 and Atg7 as inhibitors of autophagosomes formation and maturation. 
Autophagic activity was assessed in WS1 fibroblasts by two methods. First, levels of Microtubule-associated 
protein 1A/1B-light chain 3 (LC3), a central protein in the maturation of autophagosomes, were measured by 
Western blot analysis. LC3 exists in two forms; LC3 (cytosolic) and LC3ii (membrane bound). Upon autophagy 
activation, LC3i is converted into LC3ii, and the ratio LC3ii/LC3i reflects autophagic activity. Second, a 
fluorescent dye specific for autophagosomes and autolysosomes was used in a live cell setting to quantify 
autophagic vesicles (AV). 
WS1 fibroblasts were treated with Rap, Cq, or a combination of both for 24 hours and were subsequently stained 
for AV. The nuclear counterstain Hoechst 33342 served for the normalization of AV to the number of cells. Rap- 
treated cells showed no significant difference compared to untreated cells, whereas Cq treatment led to a 7.2- fold 
increase. Cells treated with a combination of Rap and Cq showed a 9-fold increase in AV compared to untreated 
cells, which was significantly higher that Cq-treatment alone [Fig. 18a]. 
Levels of LC3 proteins in WS1 treated with Rap, Cq and a combination of both for 24 hours were assessed by 
Western blot analysis. Untreated- and DMSO-treated cells served as controls. Untreated cells showed expression 
of LC3i and LC3ii, indicating basal autophagic activity. DMSO- and Rap-treated cells showed no increase in LC3 
turnover, whereas treatment with Cq or Rap+Cq led to increased abundance of LC3ii [Fig. 18b]. LC3ii abundance 
as well as LC3 ratio were higher for WS1 treated with a combination of Rap and Cq compared to cells treated 
with Cq only [Fig. 18b and 18c]. 
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Figure 18: Measurement of autophagic activity in WS1 fibroblasts. WS1 were treated with Rap, Cq or with 
a combination of Rap and Cq for 24 hours. Autophagic activity was subsequently assessed by two methods. (A) 
quantification of autophagic vesicles using a fluorescent dye, normalized to cell number. (B) Western blot analysis 
of LC3i (cytosolic) and LC3ii (membrane bound) and (C) ratio LC3ii/LC3i expressed in a bar plot. 
 
 
5.5. Stimulation of autophagy prior to SIPS induction delays the onset of senescence in 
WS1 
To assess whether autophagy is responsible for the trigger of premature senescence in WS1 fibroblasts, autophagy 
was either stimulated using Rap or inhibited using CQ for 24 hours prior to Dox-mediated induction ofsenescence. 
Autophagy and SA-β-gal activity were monitored, as previously described [Sections 4.8 and 4.9], directly after 
autophagy modulation (D-1), directly after senescence induction (D0) and at different time points during the 
recovery time [Fig. 19]. Autophagy-untreated WS1 were used as control. 
 
 
 
Figure 19: Experimental design to evaluate the relevance of autophagy in triggering senescence in WS1 
fibroblasts. Autophagy was either left unmodulated (Untd.), stimulated (Rap) or inhibited (CQ) for 24 hours 
before induction of senescence (Dox). Following Dox treatment, WS1 were allowed to recover for 13 days. 
Autophagy and SA-β-gal activity were monitored at day -1, day 0 and days 1, 2, 5, 8 and 13 using methods 
previously described. 
 
 
5.5.1. Inhibition of autophagy prior to senescence induction changes the autophagic profile 
during the development of senescence in WS1 fibroblasts 
Autophagic activity was assessed by Western blot analysis of LC3i and LC3ii [Fig. 20]. 
Untreated cells showed basal level of autophagic activity, as both forms of LC3 were detected [Fig. 20a, D-1]. 
Following Dox treatment (D0), LC3ii was greatly increased compared to D-1, indicating increased autophagic 
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activity. 1 day after Dox treatment (D1), LC3i expression was decreased compared to D-1. Abundance of LC3ii 
gradually increased during the development of SIPS (D2- D13), suggesting that autophagic activity is increased 
in senescent WS1 
Stimulation of autophagy through Rap slightly increased LC3ii abundance compared to untreated cells, indicating 
increased autophagy activity [Fig. 20b, D-1]. Directly after Dox-treatment (D0), both LC3 abundances were the 
same as in untreated cells. 1 day after Dox treatment (D1), LC3 abundances were similar as the one observed in 
untreated cells. During the development of SIPS (D2-D13), LC3 expression was similar compared to untreated 
cells. 
Inhibition of autophagy through Cq led to an increase in LC3ii and a decrease in LC3i abundances compared to 
untreated cells [Fig. 20c, D-1], indicating inhibition of the autophagic flux. Directly after Dox treatment (D0), 
LC3ii expression was higher compared to untreated and Rap treated WS1. 1 day after Dox treatment (D1), 
expression of LC3i was slightly decreased compared to untreated and Rap treated cells. During the development 
of SIPS (D2-D13), expressions of LC3i and LC3ii were significantly decreased compared to untreated and Rap 
treated cells. 
 
 
 
Figure 20: Western blot analysis of LC3i and LC3ii. Autophagy was either stimulated (Rap), inhibited (Cq) 
or left untreated (control) prior to senescence induction in WS1 fibroblasts. At different timepoints, 15 µg protein 
lysate were used to assess the expression of LC3i (cytosolic form) and LC3ii (autophagosomal form). - actin 
served as loading control. Representative pictures of 3 biological replicates are shown. 
 
 
To evaluate the autophagic flux, ratios LC3ii/LC3i [Fig. 20] were shown in a bar plot [Fig. 21]. 
Untreated cells showed basal autophagic activity [Fig. 21a, D-1]. LC3 ratio significantly increased following Dox 
treatment (D0). Although not statistically significant, LC3 ratio was higher 1 day after Dox treatment (D1), 
which is explained by the lower LC3i expression previously observed [Fig. 20a, D1]. During the development of 
SIPS (D2-D13), LC3 ratio gradually increased. 
Stimulation of autophagy through Rap slightly increased the LC3 ratio at D-1, as LC3ii abundance was higher 
compared to untreated cells [Fig 20b, D-1]. Directly after Dox treatment (D0), LC3 ratio was significantly 
higher compared to D-1 [Fig. 21b, D0], but lower compared to untreated cells. During the development of SIPS 
(D2-D13), LC3 ratio increased over time in a similar fashion as observed in untreated cells. 
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Inhibition of autophagy through Cq significantly increased the LC3 ratio, as LC3ii expression was higher 
compared to other treatments [Fig. 21c, D-1]. Directly after Dox treatment (D0), LC3 ratio was higher compared 
to other treatments. Although not significant, LC3 ratio at D0 was decreased compared to D-1 [Fig. 21, D0]. 
During the development of SIPS, LC3 ratios were slightly higher as compared to other treatments. At day 13, LC3 
ratio was not different from the one observed in other treatments. 
 
 
 
Figure  21:  Ratio  analysis  of  LC3i/LC3ii.  Autophagy  was  either  stimulated  (Rap),  inhibited  (Cq)  or  left 
untreated (control) prior to senescence induction in WS1 fibroblasts. Values obtained from Western blots [Fig. 
20] ofthree biological replicates. Means ± SEM are shown. Means compared using one-way ANOVA. Adjusted 
p-values of Turkey´s multiple comparisons tests: (****): <0.0001, (***):0.001, (**): <0.01, (*): <0.05 and (ns): 
not significant. 
 
 
5.5.2. Early stimulation of autophagy decreases SA-β-gal activity during the development of 
senescence in WS1 fibroblasts 
Senescence was measured at different time points by providing the SA-β-gal a fluorescent substrate [Fig. 22]. In 
autophagy-untreated WS1, Dox-mediated induction of senescence (D0) resulted in a 1.5-fold increase in SA- β-
gal activity compared to autophagy/senescence-untreated WS1. During the recovery time (D1-D13), levels of 
SA-β-gal activity remained significantly above the level of activity after 1 day of recovery time. D13. All 
comparisons and corresponding p-values can be found in appendix [Appendix 2a-2c, p. 106]. 
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WS1 treated with Rap before the induction of senescence showed no significant increase in SA-β-gal activity after 
Dox-treatment, or after 2 and 8 days or recovery. After 1, 5 and 13 days of recovery, SA-β-gal activity was 
significantly higher compared to Dox-untreated cells. 
WS1 treated with Cq before the induction of senescence showed a significant 1.9-fold increase in SA-β-gal activity 
compared to Dox-untreated WS1. After one day of recovery (D1), SA-β-gal activity increased significantly 
compared to day 0. During the recovery time (D2-D13), SA-β-gal activity remained significantly above the level 
of activity observed prior to senescence induction, but did not change significantly compared to day 1. 
 
 
 
 
Figure 22: SA-β-galactosidase activity when autophagy was modulated prior to SIPS induction in WS1. 
Autophagy was either (A) left untreated, (B) stimulated or (C) inhibited prior to senescence induction in WS1 
fibroblasts. At different timepoints, cellular senescence was measured using a fluorescent dye. Significances 
showed on the graph are in comparison with D-1. Values obtained from three biological replicates, each measured 
in triplicate (expression in Relative Fluorescent Units (RFU). Means ± SEM are shown. Means compared 
usingone-way ANOVA. Adjusted p-valuesof Turkey´s multiple comparisonstests: (****): <0.0001, (***):0.001, 
(**): <0.01, (*): <0.05 and (ns): not significant. 
 
 
5.5.3. Early stimulation of autophagy decreases the number of SA-β-gal positive fibroblasts 
during the development of senescence 
To validate SA-β-gal activity measurement, WS1 were stained for SA-β-gal activity [Fig. 23]. Independent of the 
treatment, WS1 developed a faint blue staining after one day of recovery (D1). After five days of recovery (D5), 
Rap-treated cells showed less intense staining compared to autophagy-untreated and Cq-treated cells. 
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WS1 treated with Cq before induction of senescence showed no visible difference compared to untreated cells at 
any time points. At day 13 (D13), all cells showed a similar senescent phenotype. 
 
 
 
Figure 23: SA-β-galactosidase staining of WS1 when autophagy was modulated prior to SIPS induction. 
Autophagy was either stimulated (Rap), inhibited (Cq) or left untreated (control) prior to senescence induction in 
WS1 fibroblasts. At different timepoints, cells were stained for SA-β-gal activity. Blue staining indicates 
senescent cells. Representative figures from three biological replicates are shown. Scalebar: 100 µM. 
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5.6. Inhibition of autophagy during SIPS development lead to cell death in WS1 
To assess whether autophagy is responsible for the development of premature senescence in WS1 fibroblasts, 
autophagy was either stimulated using Rap or inhibited using Cq for 24 hours after Dox-mediated induction of 
senescence. Autophagy and SA-β-gal activity were monitored before senescence induction (D-1), directly after 
(D0), and at different time points during the recovery time [Fig. 24]. Autophagy-untreated WS1 were used as 
control. 
 
 
 
Figure 24: Experimental design to evaluate the relevance of autophagy during the development of 
senescence in WS1 fibroblasts. During the recovery time, autophagy was either left unmodulated (UT), 
stimulated (Rap) or inhibited (Cq) for 24 hours. Following Dox treatment, WS1 were allowed to recover for 13 
days. Autophagy and SA-β-gal activity were monitored at day -1, day 0 and days 1, 2, 6, 9 and 13 using methods 
previously described. 
 
 
5.6.1. Autophagy inhibition during the development of senescence increases LC3ii in WS1 
Autophagic activity was assessed by Western blot analysis of LC3i and LC3ii [Fig. 25]. 
Untreated cells showed basal level of autophagic activity, as both forms of LC3 were detected [Fig. 25a, D-1]. 
Following Dox treatment (D0), LC3ii was greatly increased compared to D-1, indicating increased autophagic 
activity. After 1 and 2 days following Dox treatment (D1 and D2), LC3i expression were significantly decreased 
compared to D-1. During the development of SIPS (D6-D13), LC3i and LC3ii expression increases compared 
to D1 and D2. 
Directly after Dox-treatment [Fig. 25b, D0], LC3ii expression was increased compared to untreated WS1 (D- 
1), indicating that Dox treatment increases autophagy as previously observed [Section 5.6]. 1 day after Dox 
treatment (D1), LC3i expression was lower compared to untreated cells. 2 days after Dox treatment (D2), 
expressions of both LC3i and LC3ii were the same as observed in untreated WS1. During the development of 
SIPS (D6-D13), expression of LC3ii gradually increased. 
Unexpectedly, both LC3i and LC3ii expression where lower at D-1 and D0 compared to untreated and Rap treated 
WS1 [Fig. 25c, D-1 and D0]. 1 day after Dox treatment (D1), LC3ii expression was significantly higher compared 
to the one observed in untreated and Rap treated cells. During the development of SIPS (D2-D13), expression of 
LC3 did not change over time, and expression of LC3ii was significantly higher as observed in the other treatments. 
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Figure 25: Western blot analysis of LC3i and LC3ii. Autophagy was either stimulated (Rap), inhibited (Cq) 
or left untreated (control) after senescence induction in WS1 fibroblasts. At different timepoints, 15 µg protein 
lysate were used to assess the expression of LC3i (cytosolic form) and LC3ii (autophagosomal form). Β-actin 
served as loading control. Representative pictures of 3 biological replicates are shown 
 
 
To evaluate the autophagic flux, ratios LC3ii/LC3i [Fig. 25] were shown in a bar plot [Fig. 26]. 
Untreated cells showed basal autophagic activity [Fig. 16a, D-1]. LC3 ratio significantly increased following Dox 
treatment (D0). Although not significant, LC3 ratio 1 day after Dox treatment (D1) was lower compared to D0. 
Between day 2 and day 6, LC3 ratio did not change compared to day 1, but was significantly increased at day 9 
and 13. 
Stimulation of autophagy through Rap led to a similar trend in LC3 ratios compared to untreated cells [Fig. 26b]; 
directly after Dox treatment (D0), LC3 ratio was significantly higher compared to before Dox treatment (D-1). 1 
day after Dox treatment (D1), LC3 ratio was significantly lower compared to D0 and, although not significant, 
tend to increase during the development of SIPS (D2-D13). 
Inhibition of autophagy through Cq significantly increased LC3 ratios compared to cells before Dox treatment 
and directly after [Fig. 26c]. This ratio were approximatively 10-fold increases compared to untreated [Fig. 
26a] and Rap treated WS1 [Fig. 26b]. 
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Figure 26: LC3i/LC3ii ratio analysis when autophagy was modulated during the development of SIPS in 
WS1. Autophagy was either stimulated (Rap), inhibited (Cq) or left untreated (control) after senescence 
inductionin WS1 fibroblasts. Values obtained from Western blots [Fig. 25] ofthree biological replicates. Means 
± SEM are shown. Means compared using one-way ANOVA. Adjusted p-values of Turkey´s multiple 
comparisons tests: (****): <0.0001, (***):0.001, (**): <0.01, (*): <0.05 and (ns): not significant. 
 
 
5.6.2. Inhibition of autophagy during the development of senescence decreases SA-β-gal 
activity in WS1 fibroblasts 
For each treatment, SA-β-gal activity means were compared using one-way ANOVA [Fig. 27]. As previously 
observed [Fig. 22a], Dox-mediated induction of senescence significantly increased SA-β-gal activity (D0) for 
untreated and Cq-treated WS1, but not in Rap-treated cells. 
Autophagy-untreated WS1 show a significant increase in SA-β-gal activity during the recovery time (D1-D13) 
compared to untreated cells (D-1). During the recovery time, SA-β-gal activities at different time points were 
not significantly different, except for D13 [Fig. 27a]. All comparisons and corresponding p-values can be found 
in appendix [Appendix 3a-3c, p. 109]. 
WS1 treated with Rap after induction of senescence SA- β-gal activity was not different from untreated cells until 
day 6 (D6). Between day 6 and 13 (D6-D13), SA- β-gal activity was significantly higher as compared to untreated 
cells [Fig. 27b]. 
Cq-treated WS1 had significantly higher SA- β-gal activity after induction of senescence (D0). After 6 days of 
recovery time (D6), SA- β-gal activity was significantly lower as compared to untreated cells (D-1). Between day 
6 and day 13 (D6-D13), SA- β-gal activity increased and was significantly higher compared to untreated cells at 
day 13 (D13) [Fig. 27c]. 
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Figure 27: SA-β-galactosidase activity when autophagy was modulated during the development of SIPS 
in WS1. Autophagy was either (A) left untreated, (B) stimulated or (C) inhibited after induction of senescence 
in WS1 fibroblasts. At different timepoints, cellular senescence was measured using a fluorescent dye. 
Significances showed on thegraph arein comparison with D-1. Values obtained from three biological replicates, 
each measured in triplicate (expression in Relative Fluorescent Units (RFU). Means ± SEM are shown. Means 
compared using one-way ANOVA. Adjusted p-values of Turkey´s multiple comparisonstests: (****): <0.0001, 
(***):0.001, (**): <0.01, (*): <0.05 and (ns): not significant. 
 
 
5.6.3. Inhibition of autophagy during the development of senescence leads to cell death in 
WS1 fibroblasts 
Proliferating cells (D-1) showed faint staining in some cells. After Dox-treatment (D0), WS1 cells showed 
increased blue staining [Fig. 28]. Following senescence induction, WS1 were subsequently either left untreated 
for autophagy or treated with Rap (stimulation) or Cq (inhibition) for 13 days [Fig. 29]. 
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Figure 28: SA-β-galactosidase staining of untreated and Dox-treated WS1. SIPS was induced in WS1 
fibroblasts using Dox. Directly after treatment (D0, right), WS1 were stained for SA-β-gal activity. Staining of 
untreated cellsserved as control (D-1, links). Blue stainingindicatessenescent cells. Representative figures from 
three biological replicates are shown. Scalebar: 100 µM. 
 
 
After induction of senescence, autophagy-untreated cells showed SA-β-gal activity after two days (D2), which 
progressively increased until day 13 (D13). After 2 days of Rap-treatment, cells showed less staining as compared 
to untreated cells. After 6 days of Rap-treatment, no more difference could be observed between untreated and 
Rap-treated cells whereas after 13 days of Rap-treatment untreated WS1 showed deeper staining. After 2 days of 
Cq-treatment (D2), fewer SA-β-gal-positive WS1 were detected as compared to untreated cells. After six days of 
Cq treatment (D6), cell number was decreased and only some of the remaining cells showed a faint blue staining 
compared to untreated. After 16 days of Cq treatment almost no cells were left and few WS1 were SA-β-gal-
positive. 
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Figure 29: SA-β-galactosidase staining of WS1 when autophagy was modulated during the development 
of SIPS. Autophagy was either stimulated (Rap), inhibited (Cq) or left untreated (control) after induction of 
senescence in WS1 fibroblasts. At different timepoints, cells were stained for SA-β-gal activity. Blue staining 
indicates senescent cells. Representative figures from three biological replicates are shown. Scalebar: 100 µM. 
 
 
5.7. Inhibition of autophagy in senescent WS1 leads to cell death 
To assess whether autophagy is relevant for the phenotype of senescence, autophagy was either left untreated, 
or stimulated using Rap or inhibited using Cq for 24 hours in senescent WS1. Autophagy and SA-β-gal activity 
were monitored before senescence induction (D-1), after 14 days of recovery time (D14), and after 15 (D15) and 
22 days [Fig. 30]. 
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Figure 30: Experimental design to evaluate the relevance of autophagy in senescent WS1. Senescence was 
induced in WS1 and cells were allowed to recover for 14 days. Autophagy was either left untreated (UT), 
stimulated (Rap) or inhibited (Cq) for 24 hours in senescent WS1. SA-β-gal activity, autophagic activity and cell 
viability were monitored at day -1, day 14, 15 and 22 using methods previously described. 
 
 
5.7.1. Measurement of autophagic activity 
For representation purpose, LC3 ratios of untreated (D-1) and senescent cells (D14) were used for all treatment in 
Figure 31a. As previously observed [Section 5.6], untreated cells displayed basal autophagic activity, as both LC3i 
and LC3ii were detected [Fig. 31a and 31c, D-1]. As previously observed, autophagic activity is increased 14 days 
after Dox treatment, as expression of LC3i is decreased, and expression of LC3ii increased compared to untreated 
cells. [Fig. 31a and 31b, D14]. 
Unexpectedly, expression of LC3ii was slightly decreased at D15 and D22 compared to D14 [ Fig. 31a], resulting 
in a smaller LC3 ratio [Fig. 31b]. 
Stimulation of autophagy through Rap decreased LC3i expression at D15 and D22, lowering corresponding LC3 
ratios [Fig. 31b], suggesting an increased autophagic activity. 
Inhibition of autophagy through Cq gradually increased LC3ii expression (D15 and D22), significantly increasing 
corresponding ratios [Fig. 31b] and suggesting an accumulation of autophagic vesicles. 
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Figure  31:  LC3i/LC3ii  ratio  analysis  when  autophagy  was  modulated  in  senescent  WS1.  LC3ii/LC3i 
ratios were measured in non-senescent WS1 (D-1), in senescent WS1 (D14) and in senescent WS1 where 
autophagy was modulated for 1 day (D15) and 7 days (D22). (A) Western Blotof LC3. 10 µglysate from different 
time points were used. Β-actin served as loading control. Representative figure from 2 biological replicates is 
shown. (B) Ratio of LC3ii and LC3i abundance. Same data for non-senescent (D-1) and senescent (D14) are 
depicted three times. Means ± SEM are shown 
 
 
5.7.2. Measurement of SA-β-gal activity 
After 2 weeks of recovery, senescent WS1 showed a 2.6-fold increase in SA-β-gal activity compared to non- 
senescent WS1 [Fig. 32, D14], which remained constant after 1 week of treatment (D22). 
Rap-treatment showed a similar trend compared to untreated cells, whereas Cq treatment led to a decrease in SA-
β-gal activity after 1 (D15) and 7 (D22) autophagy inhibition [Fig. 32b and 32c]. Corresponding SA-β-gal staining 
can be found in appendix [Appendix 4, p. 112]. 
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Figure 32: SA-β-galactosidase activity when autophagy was modulated in senescent WS1. Autophagy was 
either stimulated (Rap), inhibited (Cq) or left untreated (control) in senescent WS1 fibroblasts. After 1 day (D15) 
and 7 days (D22) of treatment, cellular senescence was measured using a fluorescent dye. Significances shown 
on thegraph are in comparison with D-1. Values obtained from three biological replicates, each measured in 
triplicate (expression in Relative Fluorescent Units (RFU). Means ± SEM are shown. Means compared using one-
way ANOVA. Adjusted p-values of Turkey´s multiple comparisons tests: (****): <0.0001, (***):0.001, (**): 
<0.01, (*): <0.05 and (ns): not significant. 
 
 
5.7.3. Inhibition of autophagy in senescent WS1 decreases viability 
Cell viability can be determined by measuring the release of ATP in the culture medium using a luciferase-based 
assay (see section 4.14). To assess whether modulation of autophagy in senescent WS1 fibroblasts has cytotoxic 
effects, an ATP assay was performed in senescent WS1 after 3-, 6- and 9-days of autophagy modulation [Fig. 33]. 
When autophagy was left unmodified, senescent WS1 showed a significant decrease in viability after 6 days in 
culture compared to 3 days. After 9 days in culture, viability stabilized and was not different compared to 6. 
Similar trend was observed when autophagy was stimulated in senescent WS1. 
When autophagy was inhibited, viability of senescent WS1 also decreased after 6 days treatment. After 9 days 
of inhibition, viability was significantly lower as compared to days 3 and 6. 
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Figure 33: Senescent WS1 viability following autophagy modulation in senescent WS1. Autophagy was either 
left untreated, or stimulated (Rap) or inhibited (Cq) for 3-, 6-, and 9-days in senescent WS1. Cell viability 
measured using ATP assay (expression in Relative Luminescence Units). Values obtained from 8 biological. 
Means ± SEM are shown. Means compared using one-way ANOVA. Adjusted p-values of Turkey´s multiple 
comparisons tests: (****): <0.0001, (***):0.001, (**): <0.01, (*): <0.05 and (ns): not significant. 
 
 
5.8. Inhibition of autophagy in senescent Normal Human Dermal Fibroblasts decreases cell 
viability 
Results obtained in sections 5.6 and 5.7 suggest that inhibition of autophagy induces cell death in senescent 
WS1 fibroblasts. Because Cq blocks the fusion between autophagosomes with lysosomes, it was hypothesized 
that cells die due to an over-accumulation of autophagosomes. To test this hypothesis, autophagy was blocked 
in senescent Normal Human Dermal Fibroblasts (NHDF) by inhibiting the maturation of autophagosomes. 
Senescent NHDF were treated with Wortmannin (Wort), Cq, siRNA targeting Atg5 and 7 and siRNA in a 
combination with Cq. Treatments were applied for 3-, 6- and 9-days and cell viability assessed using ATP assays 
[Fig. 34a and 34b]. 
After 3 days of treatment, all autophagy inhibitors significantly decreased the viability of NHDF compared to 
untreated cells. Cell viability kept decreasing over time. After 9 days of treatment, inhibition of autophagy induced 
death of almost all senescent NHDF. All comparisons among treatments can be found in appendix [Appendix 5a-
5c]. Decreased viability of senescent NHDF was further validated by counting the number of floating cells (dead 
cells) in culture medium [Appendix 5d]. 
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Figure 34: Viability following inhibition of autophagy in NHDF. Autophagy was inhibited in senescent NHDF 
using Wort, Cq, siRNA targeting Atg5/Atg7 and in a combination with Cq for 3-, 6- and 9-days. (A) Cell viability 
measured using ATP assay (expression in Relative Luminescence Units). Values obtained from 8 biological. 
Significances shown on the graph are in comparison with untreated NHDF. Means ± SEM are shown. Means 
compared using one-way ANOVA. Adjusted p-values of Turkey´s multiple comparisons tests: (****): 
<0.0001. (B) Cell viability decrease for each treatment, expressed as percentage compared to untreated NHDF. 
 
 
5.9. Modulation of autophagy using carbohydrates 
10 sugars and sugars derivatives [Fig. 35] were tested for their ability to modulate autophagy in skin fibroblasts 
by measuring LC3 ratios and number of autophagic vesicules (AV). To further assess whether the modulation 
of autophagy was mTOR-dependent or independent, Western blot of key phosphorlyation sites of mTOR, Raptor 
and Rictor were performed. 
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Figure 35: Haworth projection of sugar structures used to modulate autophagy. (A) non-reducing sugars 
(trehalose, sucrose, raffinose and methyl-a-glucopyranoside), (B) reducing sugars (maltose, glucose and 
isomaltulose) and (C) sugars derivatives (sorbitol, gluconic acid and meglumine). 
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5.9.1. Quantification of autophagic vesicles in WS1 treated with non-reducing sugars 
WS1 fibroblasts were treated with 50 mM, 100 mM and 200 mM sugars in presence or absence of Cq for 24 hours. 
Impact on autophagy was assessed using a fluorescent dye specifically staining A). Units expressed as ratio 
CYTO-ID/Hoechst. Untreated WS1 (Untd.), as well as Rap-, Cq- and Rap+Cq-treated cells served as control. 
All non-reducing sugars tested for their ability to modulate autophagy increased AV number in a dose- dependent 
manner [Fig. 36]. 
When treated with trehalose, WS1 showed a significant 5-fold (50 mM) and 6.7-fold (100 mM) increase in AV 
as compared to untreated cells, whereas 200 mM had cytotoxic effects (data not shown) [Fig. 36a]. 
Sucrose treatment induced a significant 4.3-fold (50 mM), 6.2-fold (100 mM) or 7.6-fold increase of AV compared 
to untreated WS1 [Fig. 36b]. 
Raffinose treatment induced a significant 4.8-fold (50 mM), 6.8-fold (100 mM) or 8.9-fold increase of AV 
compared to untreated WS1 [Fig. 36c]. 
Treatment with 50 mM and 100 mM methyl-α-glucopyranoside did not impact the amount of AV compared to 
untreated cells. When WS1 were treated with 200 mM methyl-α-glucopyranoside, number of AV was 2.8-fold 
increased compared to untreated cells [Fig. 36d]. 
Treatment with sugars in the presence of Cq resulted in significant increases in AV compared to WS1 treated with 
Cq only for sucrose (100 mM and 200 mM), raffinose (100 mM and 200 mM) and methyl-α- glucopyranoside 
(100 mM and 200 mM). 
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Figure 36: Quantification of autophagic vesicles in WS1 fibroblasts treated with non-reducing sugars. WS1 
were treated with indicated concentration of (A) trehalose, (B) sucrose, (C) raffinose and (D) methyl-α- 
glucopyranoside in absence or presence of Cq. Untreated (Untd.), Rap-, Cq- and Rap+Cq-treated cells served as 
control. Level of autophagy was assessed by measuring the number of autophagic vesicle (see section 4.11). Ratios 
of fluorescent signals of CYTO-ID (autophagic vesicles) and Hoechst (nuclear dye) in WS1 after 24h treatment 
are shown. Values were obtained from n ≥ 7 biological replicates. Means ± SEM are shown. Adjusted p-values of 
Tukey’s multiple comparison test: (****): < 0.0001, (**): < 0.01, (ns): not significant. 
 
 
5.9.2. Quantification of autophagic vesicles in WS1 treated with reducing sugars 
Reducing sugars tested in the scope of this work showed variable effects on autophagy in WS1 [Fig. 27]. Tested 
at different concentrations, maltose and glucose had no effect of AV levels in WS1 compared to untreated cells. 
Levels of AV were not different from Cq-treated cells when maltose and glucose were combined with Cq. 
Treatment of WS1 with isomaltulose resulted in a significant 2.3-fold (50 mM), 3.9-fold (100 mM) and 5.7-fold 
(200 mM) increase in AV compared to untreated. In combination with Cq, isomaltulose showed increased AV 
levels as compared to Cq only. 
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Figure 37: Quantification of autophagic vesicles in WS1 fibroblasts treated with reducing sugars. WS1 were 
treated with indicated concentration of (A) maltose, (B) glucose and (C) isomaltulose, in presence or absence of 
Cq. Untreated (Untd.), Rap-, Cq- and Rap+Cq-treated cells served as control. Level of autophagy was assessed 
by measuring the number of autophagic vesicle (see section 4.11). Ratios of fluorescent signals of CYTO-ID 
(autophagic vesicles) and Hoechst (nuclear dye) in WS1 after 24h treatment are shown. Values were obtained 
from n ≥ 7 biological replicates. Means ± SEM are shown. Adjusted P values of Tukey’s multiple comparison 
test: (****): < 0.0001, (**): < 0.01, (ns): not significant. 
 
 
5.9.3. Quantification of autophagic vesicles in WS1 treated with sugars derivatives 
Sugar derivatives tested showed variable effects on autophagy in WS1 fibroblasts. Used at 50 mM and 100 mM, 
gluconic acid and meglumine did not increase AV levels in WS1 [Fig. 38b and c], whereas both had cytotoxic 
effect when used at a concentration of 200 mM (data not shown). Levels of AV detected when they were used in 
a combination with Cq were not different from Cq alone. Sorbitol induced a dose-dependent increase of AV in 
WS1 [Fig. 38a]. When used at concentrations of 100 mM and 200 mM in combination with Cq, AV levels were 
significantly higher as compared to Cq only. 
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Figure 38: Quantification of autophagic vesicles following carbohydrates treatment in WS1 fibroblasts. 
WS1 were treated withindicated concentration of(A) sorbitol, (B) gluconic acid and (C) meglumine, in presence 
or absence of Cq. Untreated (Untd.), Rap-, Cq- and Rap+Cq-treated cells served as control. Level of autophagy 
was assessed by measuring the number of autophagic vesicle (see section 4.11). Ratios of fluorescent signals of 
CYTO-ID (autophagic vesicles) and Hoechst (nuclear dye) in WS1 after 24h treatment are shown. Values were 
obtained from n ≥ 7 biological replicates. Means ± SEM are shown. Adjusted P values of Tukey’s multiple 
comparison test: (****): < 0.0001, (**): < 0.01, (ns): not significant. 
 
 
5.9.4. Effect of raffinose, maltose and isomaltose on autophagic activity 
To assess sugars ability to modulate autophagy, LC3 levels and ratio were monitored in WS1 treated with 100 
mM raffinose (non-reducing, shown to increase AV), isomaltulose (reducing, shown to increase AV) and maltose 
(reducing, with no effect on AV) by Western blot analysis [Fig. 39]. Sugars were used alone or in a combination 
with Cq. Untreated (Untd.), Rap-, Cq- and Rap+Cq served as controls. 
Untreated cells showed basal expression of LC3i and LC3ii, suggesting a basal autophagic activity. Treatment 
of WS1 with 100 mM raffinose (Raff) and 100 mM isomaltulose (Isom) increased abundance of LC3ii compared 
to untreated [Fig. 39a], while LC3i abundance did not change, resulting in higher LC3 ratios [Fig. 39b]. In 
combination with Cq, raffinose and isomaltulose increased LC3ii abundance compared to cells treated with Cq 
only. Treatment with 100 mM maltose did not change abundances of LC3ii nor LC3i compared to untreated WS1, 
resulting in a similar ratio. When used in a combination with Cq, maltose also induced increase in LC3 ratio, and 
band intensities resembled the one observed for Cq treatment only [Fig. 39a]. 
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Figure 39: Western blot analysis of LC3 in WS1 treated with 100 mM raffinose, isomaltulose and maltose. 
Treatment in the presence or absence of Cq. Untreated (untd.), Rap-, Cq- and Rap+Cq-treated cells served as 
control. (A) Western blot LC3. Following 24h treatment with sugars, proteins were isolated, and 12 µg protein 
lysate loaded. β-actin served as loading control. Representative figure of 3 biological replicates is shown. (B) 
Ratio LC3ii/LC3i. Values obtained from 3 biological replicates. Means ± SEM are shown. 
 
 
5.9.5. Effect of raffinose, maltose and isomaltose on mTOR, Raptor and Rictor 
To assess whether sugar-mediated activation of autophagy in WS1 is mTOR-dependent or independent, 
abundances and phosphorylation levels of mTOR (Ser2481), Raptor (Ser792) and Rictor (Thr1135) were assessed 
by Western blot analysis. Cells were treated with 100 mM raffinose (non-reducing, shown to increase AV), 
isomaltulose (reducing, shown to increase AV) and maltose (reducing, with no effect on AV) for 24 hours. Rap-
treated cells served as control [Fig. 40]. 
Neither Rap treatment, nortreatment with raffinose, isomaltulose or maltose induced changes in mTOR, Raptor 
or Rictor expression [Fig. 40a]. Rap treatment induced a slight migration of Rictor as compared to untreated cells 
[Fig. 40a]. Rap treatment decreased abundance of phosphorylated mTOR, while sugars had no effect [Fig. 40b]. 
Phosphorylation of Raptor on Ser792 was increased in Rap-treated cells, but did not change upon any sugar 
treatments. Rap-treated cells showed lower level of phosphorylated Rictor compared to untreated cells, whereas 
phosphorylation levels where higher upon sugars treatment [Fig. 40b]. 
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Figure 40: Western blot analysis of mTOR, p-mTOR, Raptor, p-Raptor, Rictor and p-Rictor in WS1 
fibroblasts treated with raffinose, isomaltulose and maltose. Cells were either left untreated or treated with 
100 mM sugars for 24 hours. (A) expression of mTOR, Raptor and Rictor. (B) expression of phosphorylated 
forms. 15 µg cell lysate were loaded. β-actin served as loading control. Representative figure of 2 biological 
replicates. 
 
 
5.10. APOL2, CES2, PTTG1IP and MGARP proteins are upregulated in senescent 
NHDF 
Specificsenescence markersarelackingforthetargetedeliminationofsenescentcells. Based ontheupregulated- 
proteins gene set enrichment analysis [Section 5.3], 4 biological processes were further selected for their potential 
role in senescent cell viability. For each BPs, 1 protein was chosen based on MS/MS-related criteria (number of 
unique peptides, protein coverage, number of PSMs and expression fold-change) and its novelty in the field of 
senescence. 
Expression of each protein in senescent NHDF was validated by Western blot analysis and its role in senescent 
NHDF viability assessed by siRNA-mediated gene knockdown. 
 
5.10.1. Identification and selection of Apolipoprotein L2 
Apolipoprotein L2 (APOL2) is a member of the apolipoprotein L gene family. Mainly localized in nucleoplasm 
and cytosol, it may affect the movement of lipids or allow their binding to organelles. 
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Identification of APOL2 by 2D-LC-MS/MS analysis 
Expression of Apolipoprotein L2 (APOL2) was significantly 2.45-fold higher in senescent NHDF compared to 
its expressionin proliferating NHDF(adj. p-value: 3.08E-2). Identificationof APOL2 was based onthe detection of 
4 unique peptides, covering 12.17% of the protein [Fig. 41]. Corresponding Peptide-Spectrum Matches (PSMs) 
are shown in appendix [Appendix 6a]. 
 
 
 
Figure 41: Details of APOL2 identification by 2D-LC-MS/MS. APOL2 was detected by 2D-LC-MS/MS based 
on the detection of 4 unique peptides, covering 12.17% of the protein. 
 
 
To further investigate the impact of APOL2 overexpression in senescent NHDF, biological processes and 
pathways involving APOL2 have been highlighted in the upregulated proteins GSEA map. Based on the GSEA, 
APOL2 was shown to be involved in five biological processes [Fig. 42]. 
 
 
 
 
Figure 42: APOL2-related biological processes. (A) Gene set enrichment analysis of all upregulated proteins in 
senescent NHDF. Yellow gene sets indicate biological processes where APOL2 is involved. (B) Enriched 
biological processes involving APOL2 with corresponding FDR q-values. 
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Validation of APOL2 overexpression in senescent NHDF 
Expression of APOL2 was confirmed by Western blot analysis. NHDF from 3 different donors were induced 
senescent using doxorubicin. Expression of APOL2 was assessed 1-, 10- and 20 days after Dox-treatment, and 
compared to its expression in untreated cells [Fig. 43]. 
Expression of APOL2 increased overtime in NHDF from donor 1, and was 1.3-fold higher at day 20 compared 
to untreated cells. Expression of APOL2 in untreated NHDF from donor 1 was 3.5-fold lower compared to 
untreated NHDF donors 2 and 3. In NHDF from donors 2 and 3, APOL2 expression decreased overtime and was 
approximatively 2-fold decreased at day 20. 
 
 
 
Figure 43: APOL2 expression in NHDF. NHDF were induced senescent using Dox. After 1-, 10- and 20 days, 
expression of APOL2 was compared with expression in untreated cells in 3 different donors. (A) Relative 
expression of APOL2 in donor 1, (B) in donor 2 and (C) in donor 3. Western blot analysis performed using 10 
µg lysate at different time points. β-actin served as loading control. 
 
 
5.10.2. Identification and selection of cocaine esterase 2 
Cocaine esterase 2 (CES2) is a member of the carboxylesterase large family. These proteins are responsible for 
the hydrolysis or transesterification of various xenobiotics and endogenous substrates with ester, thioester or amid 
bonds. CES2 may participate in fatty acyl and cholesterol metabolism. 
 
Identification of CES2 by 2D-LC-MS/MS analysis 
Expression of CES2 was significantly 4.3-fold higher in senescent NHDF compared to its expression in 
proliferating NHDF (adj. p-value: 4-76E-2). Identification of CES2 was based on the detection of 3 unique 
peptides, covering 6% of the protein [Fig. 44]. Corresponding Peptide-Spectrum Matches (PSMs) are shown in 
appendix [Appendix 6b]. 
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Figure 44: Details of CES2 identification by 2D-LC-MS/MS. CES2 was detected by 2D-LC-MS/MS based on 
the detection of 3 unique peptides, covering 6% of the protein. 
 
 
To further investigate the impact of CES2 overexpression in senescent NHDF, biological processes and pathways 
involving CES2 have been highlighted in the upregulated proteins GSEA map. Based on the GSEA, CES2 was 
shown to be involved in five biological processes [Fig. 45]. 
 
 
 
Figure 45: CES2-related biological processes. (A) Gene set enrichment analysis of all upregulated proteins 
in senescent NHDF. Yellow gene sets indicate biological processes where CES2 is involved. (B) Enriched 
biological processes involving CES2 with corresponding FDR q-values. 
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Validation of CES2 overexpression in senescent NHDF 
Expression of CES2 was confirmed by Western blot analysis. NHDF from 3 different donors were induced 
senescent using doxorubicin. Expression of CES2 was assessed 1-, 10- and 20 days after Dox-treatment, and 
compared to its expression in untreated cells [Fig. 46]. 
Expression of CES2 was barely detected in untreated NHDF from all donors and was 25-fold increased 1 day 
Dox-treatment. CES expression decreased overtime in all donors and was 18-fold, 14-fold and 21-fold increased 
compared to untreated cells in donor 1, 2 and 3, respectively. 
 
 
 
Figure 46: CES2 expression in NHDF. NHDF were induced senescent using Dox. After 1-, 10- and 20 days, 
expression of CES2 was compared with expression in untreated cells in 3 different donors. (A) Relative expression 
of CES2 in donor 1, (B) in donor 2 and (C) in donor 3. Western blot analysis performed using 10 µg lysate at 
different time points. β-actin served as loading control. 
 
 
5.10.3. Identification and selection of Pituitary Tumor-Transforming Gene 1 Protein- 
interacting protein 
Pituitary tumor-transforming gene 1 protein-interacting protein (PTTG1IP) is a poorly characterized protein 
though to facilitate PTTG1 nuclear translocation. 
 
Identification of PTTG1IP by 2D-LC-MS/MS analysis 
Expression of PTTG1IP was significantly 2.5-fold higher in senescent NHDF compared to its expression in 
proliferating NHDF (adj. p-value: 1.4E-4). Identification of PTTG1IP was based on the detection of 1 unique 
peptide, covering 10% of the protein [Fig. 47]. Corresponding Peptide-Spectrum Matches (PSMs) are shown 
in appendix [Appendix 6c]. Based on the GSEA, PTTG1IP was shown to be involved in 2 biological processes 
[Fig. 48]. 
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Figure 47: Details of PTTG1IP identification by 2D-LC-MS/MS. CES2 was detected by 2D-LC-MS/MS based 
on the detection of 1 unique peptide, covering 10% of the protein. 
 
 
To further investigate the impact of PTTG1IP overexpression in senescent NHDF, biological processes and 
pathways involving PTTG1IP have been highlighted in the upregulated proteins GSEA map. Based on the GSEA, 
PTTG1IP was shown to be involved in five biological processes [Fig. 48]. 
 
 
 
 
Figure 48: PTTG1IP-related biological processes. (A) Gene set enrichment analysis of all upregulated proteins 
in senescent NHDF. Yellow gene sets indicate biological processes where PTTG1IP is involved. (B) Enriched 
biological processes involving PTTG1IP with corresponding FDR q-values. 
 
 
Validation of PTTG1IP overexpression in senescent NHDF 
Expression of PTTG1IP was confirmed by Western blot analysis. NHDF from 3 different donors were induced 
senescent using doxorubicin. Expression of PTTG1IP was assessed 1-, 10- and 20 days after Dox-treatment, and 
compared to its expression in untreated cells [Fig. 49]. 
Western blot analysis showed basal expression of PTTG1IP, which increased over time following Dox- treatment 
in all donors. Following Dox-treatment, expression of PTTG1IP   increased over time and was 11- fold, 2.8-fold 
and 3-fold increased compared to untreated cells in donor 1, 2 and 3, respectively. 
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Figure 49: PTTG1IP expression in NHDF. NHDF were induced senescent using Dox. After 1-, 10- and 20 days, 
expression of PTTG1IP was compared with expression in untreated cells in 3 different donors. (A) Relative 
expression of PTTG1IP in donor 1, (B) in donor 2 and (C) in donor 3. Western blot analysis performed using 10 
µg lysate at different time points. β-actin served as loading control. 
 
 
5.10.4. Identification and selection of MGARP protein 
Protein MGARP (MGARP) plays a role in the trafficking of mitochondria and is also involved in mitochondria 
abundance and morphology. 
 
Identification of MGARP by 2D-LC-MS/MS analysis 
Expression of MGARP was significantly 2.2-fold higher in senescent NHDF compared to its expression in 
proliferating NHDF (adj. p-value: 2.25E-2). Identification of MGARP was based on the detection of 6 unique 
peptides, covering 47% of the protein [Fig. 50]. Corresponding Peptide-Spectrum Matches (PSMs) are shown 
in appendix [Appendix 6d]. Based on the GSEA, MGARP was shown to beinvolved in nine biological processes 
[Fig. 51]. 
MGARP was not detected by Western blot analysis, neither in proliferating nor senescent NHDF. 
69 
 
 
 
 
Figure 50: Details of MGARP identification by 2D-LC-MS/MS. CES2 was detected by 2D-LC-MS/MS based 
on the detection of 6 unique peptides, covering 47% of the protein. 
 
 
To further investigate the impact of MGARP overexpression in senescent NHDF, biological processes and 
pathways involving PTT MGARP G1IP have been highlighted in the upregulated proteins GSEA map. Based 
on the GSEA, MGARP was shown to be involved in five biological processes [Fig. 51]. 
 
 
 
 
Figure 51: MGARP-related biological processes. (A) Gene set enrichment analysis of all upregulated proteins 
in senescent NHDF. Yellow gene sets indicate biological processes where MGARP is involved. (B) Enriched 
biological processes involving MGARP with corresponding FDR q-values. 
 
 
Possible role of MGARP in mitochondria structure and abundance 
Although MGARP was not detected by Western blot analysis, its detection by 2D-LC-MS/MS suggest an 
impairment of mitochondria abundance and structure in senescent NHDF. To validate this hypothesis, electron 
microscopy was performed on proliferating and senescent NHDF. 
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Mitochondria of proliferating NHDF had an oval shape, whereas mitochondria from senescent NHDF were 
enlarged and branched [Fig. 52]. Mitochondria number was decreased in senescent compared to proliferating 
NHDF (visual observation, data not shown). 
 
 
 
Figure 52: Electron microscopy of NHDF. NHDF were induced senescent using Dox. After 14 days, 
proliferating (control) and senescent NHDF were cryo-fixed, embedded and sectioned for electron microscopy 
(See section 4.15). (A) proliferating NHDF, with a focus on mitochondria (red square). (B) Senescent NHDF with 
a focus on mitochondria (red square). 
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5.11. APOL2, CES2, PTTG1IP and MGARP play a role in senescent NHDF viability 
NHDF were induced senescent using Dox and allowed to recover for 14 days. At day 14, cells were treated with 
siRNA against APOL2, CES2, PTTG1IP and MGARP for 3 days. Lysis buffer, transfection reagent only 
(Transf), siRNA targeting GAPDH and scrambling siRNA served as control. After three days treatment, cell 
viability was assessed by ATP assay [Fig. 53]. 
After three days treatment, cell viability was significantly decreased for all four protein knockdowns. Viability 
of cells treated with siRNA targeting GAPDH was also significantly decreased compared to untreated cells. 
 
 
 
Figure 53: NHDF viability following APOL2, CES2, PTTG1IP and MGARP knock down. Senescent NHDF 
were treated for 3 days with siRNA targeting APOL2, CES2, PTTG1IP and MGARP. Lysis buffer, transfection 
reagent, scramble siRNA and siRNA targeting GAPDH served as control. 
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6. Discussion and outlook 
 
 
6.1. Proteome analysis of senescent Normal Human Dermal Fibroblasts 
To understand mechanisms of aging and age-related diseases, numerous studies in transcriptomics, metabolomics 
and proteomics have been conducted. For the past decade, research in senescence proteomics has been carried out 
using different methods as two-dimensional gel electrophoresis (2D-GE)151,152 and two- dimensional differential 
gel electrophoresis (2D-DIGE)153, providing limited efficiency for protein identification and quantification. Recent 
advances in liquid chromatography-tandem mass spectrometry (LC-MS/MS) made this technology an excellent 
tool for large proteomics analysis and allowed for the identification of several senescence markers154,155. 
 
6.1.1. Differentially expressed proteins in senescent normal human dermal fibroblasts 
Whole proteome analysisofnormal human dermal fibroblasts(NHDF) was conducted by 2-Dimensional Liquid 
Chromatography-tandem Mass Spectrometry. To detect low abundance peptides, often masked by highly 
abundant peptide peaks, NHDF protein samples were first fractionated by strong cation exchange 
chromatography, as previously described156,157. Further analysis of sample fractions by conventional LC- MS/MS 
allowed the identification of 4147 proteins [section 5.2], significantly contributing to previous studies158-161. 
Senescence-specific biomarkers are lacking162. Among the 4147 proteins previously identified, 20 and 19 proteins 
were specifically expressed in proliferating and senescent NHDF, respectively (Table 1a and 1b, p. 36 and 37). 
These proteins could be of interest for the identification and elimination of senescent cells and add knowledge 
to similar studies151,163. Nevertheless, extensive studies are required to confirm their overexpression in senescent 
NHDF, as well as in other cell types and with different senescence-inducers. 
Proteomics technologies allow high throughput but are of limited use for the identification of novel drug targets 
due to difficult detection of low abundance proteins in complex protein mixes. The entire human genome codes 
for 21´000 canonical proteins and although fibroblasts-specific proteome is not fully characterized, the 4147 
proteins identified by 2D-LC-MS/MS [section 5.2] might be a small part of it. 
Cellular signaling and mechanisms often rely on reversible post-translational modifications (PTMs)164, consisting, 
among other, of reversible addition of alkyl and acyl chains, sugars and phosphate groups to the protein165. 
Phosphorylation is a protein   activator/deactivator and has been shown to affect   13000 proteins of the whole 
proteome (2/3). Around 90% of proteins are predicted to undergo phosphorylation and dephosphorylation cycles, 
underlying the importance of this PTM in cellular mechanisms166. 
A recent study on fibroblasts phospho-proteome identified 494 unique peptides with single or multiple 
phosphorylation sites undergoing phosphorylation cycles under irradiation, highlighting the importance of this 
post-translational modification in signal transduction167 . Interestingly, corresponding proteins are involved in cell 
cycle checkpoint control, DNA damage response and apoptosis, which are also impaired processes in senescence. 
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Because cellular processes and signal transduction are mostly regulated via PTMs-mediated 
activation/inactivation of proteins, further PTMs-omics studies are required to provide more knowledge about 
cellular senescence mechanisms. Finally, lipid- and sugar-, as well as protein secretion-related biological 
processes (BPs) were impaired in senescent NHDF [Fig. 16, p. 41], suggesting that lipidomics, glycomics and 
secretomics should also be considered for senescence studies. 
 
6.1.2. Gene Set Enrichment Analysis 
Gene set enrichment analysis (GSEA) is a bioinformatic tool helping to identify biological pathways that are 
enriched in a gene list generated from -omics experiments150,168. To gain mechanistic insight into senescent NHDF 
down- and up-regulated proteins, GSEA was conducted using g:Profiler web tool and mapped using Cytoscape 
and EnrichmentMap software. 
 
Downregulated proteins enrichment analysis 
Along with BPs expected to be enriched in senescence downregulated proteins list [Table 2, p. 40], viral defense 
related mechanisms accounted for a significant portion of all enriched BPs [Appendix 1a and 1b, p. 103], 
indicating a correlation with senescence. This link was further strengthened by the identification of similar 
mechanisms in upregulated proteins enrichment analysis (data not shown). Proinflammatory-related BPs were 
also found enriched in GSEA of upregulated proteins, certainly reflecting the Senescence-Associated Secretory 
Phenotype (SASP); Senescent cells are metabolically active and secrete different factors to the extracellular 
environment. Made of chemokines, cytokines and matrix metalloproteases, the SASP is known to have 
proinflammatory properties84,169. 
Along with the ability of some viruses to inhibit cellular senescence, it has been hypothesized that senescence has 
evolved as a protective mechanism against viral infections170. 
Mounting evidences show that many viruses also hijack the autophagy machinery for their replication cycle171- 
173. The recent coronavirus outbreak (COVID-19) urges the scientific community to rapidly find therapeutic 
options, and the repurposing of drugs that are already approved and on the market makes for a good first step in 
fighting the virus. In this context, chloroquine (approved by the Food & Drug Administration (FDA) in 1949 for 
the treatment of malaria) is currently being tested in clinical trials for its potential ability to interfere with COVID-
19 life cycle. 
When entering the cell, the non-protonated portion of chloroquine becomes protonated and concentrates in 
organelles such as endosomes and lysosomes, where it increases the pH174. Fifteen years ago, Vincent et al. 
showed that the effect of chloroquine on coronavirus infection is also explained by the effect of the drug on the 
glycosylation of a cellular receptor involved in the virus entry175. 
Although preliminary tests suggest benefic effects on COVID-19 infection176-178, whether chloroquine impacts 
virus life cycle through basification of vesicles, cellular receptor modification orautophagy-related inhibition of 
senescence remains to be clarified. Nevertheless, this support the hypothesis that senescence, autophagy and viral 
defenses are interconnected mechanisms. 
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The data show that viral defense mechanisms are impaired during senescence, possibly rending senescent cells 
more sensitive. Whether these findings can be exploited to modulate cellular senescence remains unexplored 
and might lead to innovative approaches for the elimination of senescent cells. 
 
Upregulated proteins enrichment analysis 
Aging is accompanied with a decrease in autophagic activity. In the context of senescence, it has been shown to 
be increased in order to support metabolic needs and survival of senescent cells. 
Upregulated proteins enrichment analysis identified autophagy as a major cluster of biological processes in 
senescent NHDF, accounting for approximately 8% of all biological processes [Fig. 17, p. 42]. However, the exact 
role of autophagy in the context of senescence remains unclear. 
 
6.2. Relevance of autophagy in the context of cellular senescence 
Bothsenescence and autophagy have been describedas cytoprotectivemechanisms, suggestingsimilarorshared 
molecular regulation137. Reports where the role of autophagy in the context of senescence was assessed are 
conflicting. 
To better understand the role of autophagy in the context of stress-induced premature senescence in skin 
fibroblasts, autophagy was modulated in three different experimental setups. Autophagic flux was either 
stimulated or inhibited (1) before the induction of senescence, (2) during the development of senescence and (3) 
in senescent normal human dermal fibroblasts [Fig. 19, 24 and 30, p. 44, 49 and 55, respectively]. SA-β-gal 
activity and autophagic activity were monitored at different time points, as previously described. 
 
6.2.1. Stimulation of autophagy delays the onset of senescence in skin fibroblasts 
Autophagy has been shown to promote cellular senescence, as functional autophagy accelerates the onset of 
cellular senescence179,180. Slobodnyuk et al. recently reported that induction of autophagy by p38α promotes 
cellular senescence181. 
The results obtained in the scope of this work show that Rap-mediated stimulation of autophagy before the 
induction of senescence delays its onset, as shown by an average decrease in the SA-β-gal activity of 7% compared 
to untreated WS1 [Fig. 22b vs 22a, p. 47]. Similarly, Rap-mediated stimulation of autophagy during the 
development of senescence delays its onset, as shown by an average decrease in the SA-β-gal activity of 12% 
compared to untreated WS1 [Fig. 27b vs 27a, p. 52]. Although autophagy stimulation delays the onset of 
senescence, it cannot prevent it, as no difference in SA-β-gal activity or staining were observed at day 13 compared 
to untreated WS1 [Fig. 22b vs 22a and Fig. 27b vs 27a, p. 47 and 52, respectively]. 
These observations were further validated by SA-β-gal staining of Rap-treated WS1, which show fewer senescent 
positive cells (blue staining) compared to untreated [Fig. 23, page 48 and Fig. 29, p. 54]. Nevertheless, SA-β-gal 
staining intensity in senescent cells has been reported to be decreased upon Rap treatment without 
affectingthecellcycle182,183, whichcould explainwhy SA-β-galstainingof Rap-treated WS1 appears less intense 
compared to untreated cells [Fig. 23, p. 48]. The stimulation of autophagy in Dox-treated WS1 keeps a spindle- 
75 
 
 
 
like morphology in opposition to untreated cells [Fig. 29, p. 54], indicating a likely influence of Rap on the cellular 
metabolism with beneficial effects on senescent cells survival. If this is due to an increased autophagic activity or 
mTOR inhibition related mechanisms remains to be determined, as single rapamycin treatment has been shown 
to persistently change the proteome and metabolome of cells184. 
Rap-mediated stimulation of autophagy in senescent WS1 has no effect on SA-β-gal activity compared to 
untreated cells [Fig. 32b vs 32a, p. 57], highlighting the irreversible character of cellular senescence. 
Together, these observations are consistent with previous studies which showed that autophagy prevents the onset 
of senescence185,186. This takes place in a larger context describing autophagy as a protective mechanism increasing 
organism and cellular lifespan by decreasing the rate at which cellular damages accumulate187-189. 
These results also correlate with the observations of Han et al., reporting a preventive effect of Rap treatment 
on replicative senescence in human dermal fibroblasts185. Nevertheless, they did not provide clear evidence that 
Rap-mediated increase of autophagic flux is sufficient for this protective mechanism, as Rap was also shown to 
have multiple beneficial effects on serially passaged human skin fibroblasts, including notably protection against 
telomere shortening, DNA methylation and increased stress resistance190. 
Lerner et al. provided compelling evidences that autophagy-mediated clearance of dysfunctional mitochondria 
(mitophagy) is one aspect contributing to the prevention of replicative senescence in human dermal fibroblasts186. 
Contradictorily, Young et al. reported that autophagy contributes to, and accelerates the onset of oncogene-
induced senescence (OIS) in human fibroblasts180. The mechanisms involved in replicative senescence and OIS 
differ from Dox-induced senescence, emphasizing the need to distinguish between different types of senescence 
and autophagy. 
 
6.2.2. Inhibition of autophagy after induction of premature senescence leads to cell death in 
skin fibroblasts 
It has been reported autophagy impairment triggers premature senescence191-193. 
The results obtained in this work show that inhibition of the autophagic flux in WS1 through Cq treatment before 
the induction of senescence decreases SA-β-gal activity, as shown by an average drop of ~40% compared to 
untreated cells (D-1). After Dox-mediated induction of senescence (D1 – D13), SA-β-gal activity was on average 
3% higher compared to untreated cells [Fig. 22a vs 22b and 23, p. 47], suggesting that autophagy impairment 
positively impact the development of senescence. This is in concordance with the observation of Fujii et al., who 
showed that insufficient autophagy promotes senescence194. 
In counterpart, inhibition of autophagy during the development of senescence prima facie decreased the SA-β- 
gal activity until 9 days after Dox-treatment [Fig. 27c, p. 52]. This decrease by 33% in SA-β-gal activity was 
further correlated with viability of senescent WS1 treated with Cq [Fig. 29 and 33c, p. 54 and 58, respectively], 
indicating that blocking autophagic flux during the development of senescence changes the cell fate from 
senescence to cell death. 
These findings are supported by multiple reports, indicating that autophagy inhibition change the cell fate from 
senescence development to apoptosis195-196. Cavinato et al. provided evidences that autophagy inhibition is 
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sufficient to switch cell fate from senescence to apoptosis179. Consistently, Singh et al. showed that autophagy- 
mediatedremovalofp18-CycE(afragmentofcyclin     E)     favorizessenescenceuponapoptosisandthatimpairment of 
autophagy reverts the cell fate to apoptosis in epithelial carcinoma cells195. 
The cytotoxic effect of Cq seems to be specific to senescent cells, as the SA-β-gal activity increased again from 
day 9 [Fig. 27c, p. 52]. This could be explained by time-differential adoption of the senescence phenotype 
following Dox-treatment, resulting in a mixed population of proliferating (slowly turning senescent) and (already) 
senescent WS1. Until day 6, senescent cells die upon Cq treatment, which decreases the overall SA-β- gal activity. 
From day 9, previous proliferating WS1 turned senescent, increasing the SA-β-gal activity. The mixed population 
hypothesis, as well as the ability of Cq to specifically induced cell death in senescent WS1 was confirmed by SA-
β-gal staining: after 13 days of autophagy inhibition (Cq), cell density was decreased by approximatively 84% 
compared to untreated WS1. Furthermore, the absence of SA-β-gal positive cell (blue staining) upon CQ treatment 
strengthens the hypothesis of the “senescence-apoptosis switch” described above [Fig. 29, p. 54]. 
Similarly, the apparent decrease in SA-β-gal activity observed upon Cq treatment in senescent WS1 [Fig. 32a 
vs 32c, p. 57] is correlated with cell death, as shown by a decrease of 42% (6d) and 75% (9d) of senescent WS1 
viability. 
As both Rap and Cq do not affect autophagy specifically, but also other cellular processes, results gathered from 
these experiments need to be carefully revised. In this context, Mizushima et al. shows how challenging it is to 
draw conclusions on the function of autophagy in a biological context where autophagy was pharmacologically 
inhibited197. Therefore, these results need to be further confirmed by genetic knock out of essentials genes involved 
in autophagy. Similarly, Rap is not a specific inducer of autophagy, as inhibition of its target (mTORC1) affects 
multiple cellular processes, including overall proteome and metabolome198. 
 
 
 
Figure 54: Role of autophagy in the context of cellular senescence (graphical summary). (A) Autophagy was 
modulated before Dox-mediated induction of senescence in WS1. Following Dox treatment, SA-β-activity 
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increased over time (UT). When autophagy is stimulated (Rap), the SA-β-activity is lower during the development 
of senescence compared to untreated (UT) and autophagy inhibited WS1 (Cq). When autophagy is inhibited 
(Cq), SA-β-activity is higher compared to the other groups. Neither stimulation nor inhibition of autophagy prior 
to senescence induction could avoid its establishment. (B) Autophagy was modulated during the development of 
senescence. Together, these data show that early stimulation of autophagy delays the onset of senescence, while 
its inhibition worthens the activity of the SA-β-activity. When autophagy is modulated after the induction of 
senescence, its stimulation results in lower SA-β-activity compared to untreated WS1, whereas its inhibition 
induce cell death. 
 
 
6.2.3. Autophagy inhibition per se is responsible for senescent fibroblasts death, and not CQ 
treatment 
Chloroquine is a potent autophagy inhibitor and has been shown to block the fusion autophagosome-lysosome199. 
To exclude that cell death observed upon Cq treatment is the result of an accumulation of vesicles in the 
cytoplasm, autophagy was inhibited by blocking phagosome formation and maturation in senescent NHDF. 
After 3 days of inhibition, senescent NHDF viability decreased by more than 50% for all autophagy inhibitors, 
except Wort (26%). After 6 days, viability decreased by more than 80% (Wort 60%) and after 9 days by more 
than 90% (Wort 50%) [Fig. 34, p. 59]. Together, this reinforces the hypothesis that decreased viability of 
senescent NHDF is a consequence of autophagy-inhibition and not a of the Cq treatment. 
Potent and irreversible inhibitor of phosphatidylinositol 3-kinase (PI3K), an enzyme required for autophagy200- 
201, Wortmannin (Wort) induced significant decrease in senescent NHDF viability [Fig. 34a to 34c, p. 59]. PI3K 
is known to be involved in Toll-like receptor (TLR) signaling, mediating the glycolytic reprogramming of cells202. 
Because glycolysis has been shown to be increased in senescent human fibroblasts203, whether Wort- induced cell 
death observed in senescent NHDF is due to autophagy inhibition or glycolysis impairment needs to be further 
explored. 
Autophagy related proteins 5 and 7 (Atg5 and Atg7) are essential proteins involved in autophagosomes 
maturation, and their depletion have been extensively used as a tool to inhibit autophagy204,205. Atg proteins have 
recently been shown to regulate many cellular processes, as depletion of Atg5 impacts 15% of the total 
proteome206. This could explain the decrease in senescent NHDF viability following Atg5/7 depletion [Fig. 34a 
to 34c, p. 59]. This is supported by a recent publication, highlighting an Atg5/ Atg7-independent alternative 
autophagy occurring under certain stresses207. Thus, whether Atg depletion-mediated cell death observed in 
senescent NHDF is a consequence of autophagy inhibition or of changes in the proteome needs to be further 
investigated. 
Acting as a receptor for ubiquitinated proteins during selective (basal) autophagy, p62 increases when autophagy 
is inhibited208. High levels of p62 have been shown to delay the clearance of tagged-cargo by the ubiquitin- 
proteasome system209. Thus, Cq-mediated inhibition of autophagy could also result in a decrease activity of the 
proteasome, leading to the accumulation of damaged proteins and organelles. 
Senescent fibroblasts exhibit elongated mitochondria [Fig. 52, p. 75]. Under normal conditions, these 
mitochondria are removed by a specific ubiquitin/p62 dependent selective autophagy, called “mitophagy”. 
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Weather Cq-mediated inhibition of autophagy impairs the removal of dysfunctional mitochondria, thus increasing 
cellular damages, needs to be validated. 
Accumulation of p62 plays a role in cell survival. Organized in “speckles”, p62 interact with both TRAF6 and 
caspase 8. The binding of p62 with TRAF6 activated the NK-κB signaling and promotes cell survival. The binding 
of p62 with caspase 8, in counterpart, triggers apoptosis. The exact mechanism deciding which pathway should 
be activated remains unclear, but Cq-mediated inhibition of autophagy might increase p62 levels and triggers the 
apoptotic pathway through caspase-8 activation in senescent skin fibroblasts. 
 
6.2.4. Is autophagy sufficient for senescence induction in WS1? 
To assess whether the modulation of autophagy is sufficient to trigger senescence in Dox-treated WS1, autophagic 
activity was measured during the development of senescence [Fig. 19, 24 and 30, p. 44, 49 and 55, respectively]. 
Autophagy was monitored in two different set-ups, (1) by staining autophagosomes and (2) by calculating the 
ratio LC3i/LC3ii. Autophagy works as a flux, a measure of autophagic degradation activity210. Rap-mediated 
stimulation of autophagy increases the rate at which autophagosomes are produced and matured, and also at which 
they are degraded by fusing with lysosomes. This increased turnover explains why stimulation of autophagy does 
not return a different signal compared to untreated cells [Fig. 18a and 18c, p. 43]. Similarly, blocking the fusion 
autophagosome-lysosome through Cq treatment leads to an accumulation of autophagosomes, responsible for the 
increase in autophagic vesicles [Fig. 18a, p. 43] and LC3 ratio observed [Fig. 18c, p. 43]. The autophagic activity 
can be evaluated by the LC3i (cytosolic) and LC3ii (membrane-bound) expressions, separately [Fig. 18b, p. 43]. 
When WS1 are left untreated, 76% of LC3 protein is under its cytosolic form (LC3i) and 24% is membrane-bound, 
indicating a basal autophagic activity. Upon Rap treatment, LC3i expression is 30% lower compared to untreated, 
indicating an increased turnover in the production/degradation of autophagosomes. Upon Cq treatment, LC3ii 
expression is 214% higher compared to untreated and is explained by the accumulation of autophagosomes. 
Directly after Dox treatment (D0), autophagic activity is increased in WS1 fibroblasts, as expression of LC3ii is 
higher compared to untreated cells (D-1) [Fig. 20 and 25, p. 45 and 50, respectively]. 
This is in opposition with recent studies showing that Dox treatment induces dysfunction and impairment of 
autophagic flux211,212. 
One day after Dox treatment (D1), expression of LC3ii was decreased compared to untreated cells (D-1) and 
compared to cells directly after Dox treatment (D0) [Fig. 20a-20c and Fig. 26a, 26b, p. 45 and p. 51, respectively]. 
Two day after Dox treatment (D2), expressions of LC3i and LC3ii were the same as compared to untreated cells, 
suggesting the recovery of a basal autophagic activity. 
During the development of SIPS (D2-D13), abundance of LC3i remains unchanged, whereas LC3ii expression 
gradually increases overtime in untreated cells [Fig. 20a and 26a, p. 45 and 51, respectively] as well as in cells 
treated with a single dose of Rap [Fig. 20b, p. 45]. These observations suggest that development of SIPS is 
accompanied with increase autophagic activity. 
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The decrease in both LC3 abundances observed at day 1 (D1) rises two hypotheses. First, the low detection signal 
could be the result of a decrease in autophagic activity, as the abundance of both cytosolic and membrane- bound 
forms of LC3 is decreased. This would mean that, following Dox-treatment, WS1 engage the senescence program 
because of an impaired autophagic activity. This is supported by different reports, showing that impairment of 
autophagy induces premature senescence213,214. 
Second, the low LC3 abundances could be explained by an extreme increase in autophagic activity, where the 
acceleration of theturnover production/elimination ofautophagic vesicles diminishes the detection of LC3. This 
would mean that, following Dox-treatment, WS1 engage the senescence program because of an increased extreme 
increase in the autophagic flux. This hypothesis is supported by the work of Slobodnyuk et al, which recently 
highlighted the role of p38α-mediated increased of autophagy in the development of senescence181. 
The data suggest that an extreme stimulation of autophagy is involved in the development of senescence in WS1 
fibroblasts. This is supported by the fact that inhibition of autophagy through several inhibitors (Cq, Wort and 
siRNA Atg5/7) does not trigger senescence, but induces cell death during the development of SIPS and in 
senescent WS1 [Fig. 29, Fig. 33 and Fig. 34, p. 54, 58 and 59, respectively]. 
Whether this extreme autophagic activity is sufficient to trigger senescence in WS1 needs to be further 
investigated. For example, an experimental setup where autophagy is stimulated inthe absence of Dox-mediated 
induction of SIPS could answer this question. 
These data suggest a switch in the autophagic flux occurring between day 0 and day 2 [D0-D2, Fig. 20 and Fig. 
25, p. 45 and 50, respectively], changing the cell fate from basal autophagy to autophagy-mediated induction of 
senescence. Differential proteomics, aiming to compare the proteome of WS1 where autophagy was modulated, 
could potentially identify modulators of this switch. 
6.3. Carbohydrates-mediated modulation of autophagy in WS1 
From a broader perspective, these data show the effect of autophagy in the context of senescence; Early stimulation 
of autophagy delays its onset, whereas inhibition of autophagy in senescent skin fibroblasts leads to cell death. 
The identification of autophagy modulators is a promising therapeutic approach to counter cellular senescence. 
For their safety of use, sugars are extensively evaluated for their ability to modulate autophagy, which led to the 
recent identification of trehalose, raffinose and sucrose as mTOR-independent activator of autophagy in 
keratinocytes136. 10 sugars or sugars-derivatives were tested for their ability to modulate autophagy in WS1 
fibroblasts [Fig. 35 p. 60]. 
All non-reducing sugars, as well as isomaltulose and sorbitol (sugars derivatives), increased in a dose-dependent 
manner the number of autophagic vesicles in WS1 fibroblasts [Fig. 36a – 36d, Fig. 37c and Fig. 38a, p. 62, 63 and 
64, respectively]. Maltose and glucose (reducing sugars), as well as gluconic acid and meglumine (sugars 
derivatives) had no effect [Fig. 37a and 37b, Fig. 38b and 38c, p. 63 and 64, respectively]. 
The number of autophagic vesicles detected upon trehalose treatment in a combination with Cq was not different 
from Cq alone [Fig. 36a p. 62], suggesting an inhibitory effect. All other sugars and sugar derivatives tested 
showed an increased number of autophagic vesicles when used in combination with Cq compared to Cq alone, 
suggesting an increased autophagic flux. The sugars alone increased the number of autophagic vesicles, while Rap 
treatment did not. This indicates that the signal is a result from impaired autophagosome degradation. 
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To further validate these data [Fig. 36 to 38, p. 62, 63 and 64, respectively], LC3 abundance following raffinose, 
isomaltulose and maltose treatments where assessed by Western blot [Fig. 39a, p. 65]. Upon raffinose treatment, 
previously shown to increase autophagic vesicles [Fig. 36c, p. 62], expression of LC3ii was higher compared to 
untreated cells. For the reason explained above, this indicates an increase in autophagic activity. For the same 
reason, LC3 ratio was not different from Rap [Fig. 39b, p. 65]. In counterpart, isomaltulose and maltose did not 
impact LC3ii expression, suggesting that they did not stimulate autophagy. The increase in autophagic vesicles 
observed upon isomaltulose treatment [Fig. 37c, p. 63] need to be further investigated, as it is not clear whether 
it activates or inhibits autophagy. 
Whether trehalose is an autophagy activator or inhibitor is debated. Whereas Yoon et al. described it as potent 
autophagic flux inhibitor215, recent work of Chen et al. suggests an activator effect in keratinocytes136. To 
adjudicate on the role of trehalose, 3 weeks-old senescent NHDF were treated with 50, 100 and 200 mM trehalose 
for 3-, 6- and 12 days, and cell viability assessed using ATP assay [Appendix 7, p. 118]. Due to repeated medium 
change, the viability of old senescent NHDF decreases in vitro over time [Appendix 7, p. 118]. Trehalose treatment 
led to an increase in old senescent NHDF viability, which was systematically higher compared to untreated cells 
at day 3, 6 and 12. As data generated in the frame of this work indicate that inhibition of autophagy in senescent 
NHDF leads to cell death, trehalose might be considered as an activator of autophagy in senescent NHDF. 
Trehalose plays a role in energy metabolism in yeast216-218, as inhibitor of hexokinases (glycolytic enzymes 
responsible for the transformation of glucose into glucose-6-phophate). Whether increased viability of old 
senescent NHDF treated with trehalose is due to increased autophagic activity or changes in glucose metabolism 
needs to be further investigated. 
Exact mechanisms underlying sugars-mediated modulation of autophagy remain poorly understood. It is thought 
that, by opposition to Rap, sugars modulate autophagy in an mTOR-independent fashion136. Western blot analysis 
of mTOR, Raptor and Rictor (key components of the mTOR-mediated autophagy) showed that neither raffinose, 
nor isomaltulose or maltose change the expression or activation of these proteins [Fig. 40a, p. 66]. Since mTOR 
activity is regulated via phosphorylation cycles, it was assessed whether key phosphorylation sites were modified 
upon Rap and sugars treatments [Fig. 40b, p. 66]. 
The phosphorylated form of mTOR (p-mTOR) was lower upon Rap treatment, as previously shown136. Upon 
raffinose, isomaltulose and maltose treatments, p-mTOR levels were similar as in untreated cells, suggesting that 
none of these sugars impact the mTOR-mediated autophagic machinery. 
Upon starvation, autophagy is activated through both mTORC1 inhibition and AMPK activation, AMPK ensuring 
mTORC1 inhibition through phosphorylation of Raptor at Ser792220. Consequently, unchanged phosphorylation 
levels of Raptor-Ser792 upon any treatment compared to untreated cells assured that autophagy was not activated 
through starvation conditions. 
Julien et al. reported that mTORC1-activated S6K1 mediated the phosphorylation of Rictor on Thr1135221. 
Western blot analysis following Rap treatment shows that phosphorylation levels of Rictor (Thr1135) are 
decreased compared to untreated cells. Thisindicatesthat Rap inhibited mTORC1 activity byinactivating S6K1, 
consequently decreasing phosphorylation levels of Rictor on Thr1135. Interestingly, treatment with raffinose, 
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sucrose and maltose increased the phosphorylation level of Rictor, indicating a mTOR-dependent modulation 
of autophagy [Fig. 40b, p. 66]. 
Whether phosphorylation of Rictor on Thr1135 affects Akt-Ser473 phosphorylation, a downstream target of 
mTORC2, remains debated221. Neither mTORC2 integrity nor its kinase activity are impaired upon Rictor- 
Thr1135 phosphorylation222. However, phosphorylation of Thr1135 was shown to inhibit the association of Rictor 
with cullin-1, forming a functional E3 ubiquitin ligase223. This indicates that the phosphorylation site on Thr1135 
could play a role in mTORC2-independent functions of Rictor within the cell221. Together, this suggest that Rictor-
Thr1135 might not be an optimal target to assess whether autophagy modulation appears to be mTOR 
independent. In future studies, evaluating the activity of downstream targets of mTORC1 such as ULK1 should 
provide more information about whether autophagy is activated in an mTOR-dependent or independent manner. 
 
6.4. APOL2, CES2, PTTG1IP and MGARP are potential targets for the elimination of 
senescent skin fibroblasts 
Identification of unique and specific markers allowing one to identify and quantify senescent cells in vivo and in 
vitro is challenging224. To find novels markers of skin fibroblasts senescence, 4 proteins (APOL2, CES2, PTTG1IP 
and MGARP) were selected from 2D-LC-MS/MS analysis [Fig. 12, p. 37]. Upregulated in senescent NHDF, their 
potential role in senescent fibroblasts viability was assessed by gene knockdown. 
 
6.4.1. Apolipoprotein L2 (APOL2) 
APOL2 is thought to affect lipids metabolism, movement and their binding to organelles225. This was confirmed 
by upregulated proteins enrichment analysis [Fig. 42a, p. 68]. Further expression validation by   Western blotting 
showed variation among the 3 different fibroblasts donors, where only donor 1 had increased APOL2 expression 
20 days after SIPS induction [Fig. 43, p. 69]. Nevertheless, siRNA-mediated knockdown of APOL2 in donor 3 
resulted in a decreased cell viability after 3 days treatment, suggesting that APOL2 could be used as therapeutic 
target for the specific elimination of senescent skin fibroblasts [Fig. 53, p. 76]. 
Role of APOL2 in the context of senescence remains unexplored. Recently, Luo et al. showed that cytosolic 
APOL2 is widely expressed in different cell type, and is induced by interferon-gamma during aging226. As 
interferon-gamma signaling was found enriched in GSEA, further studies need to be conducted to assess whether 
decreased viability of senescent NHDF observed following knockdown of APOL2 is the result of an impairment 
in the interferon-gamma signaling, or if inhibition of APOL2 is sufficient. 
 
6.4.2. Cocaine esterase 2 (CES2) 
CES2 plays a role in detoxification of xenobiotics227 and lipid metabolism228. This was confirmed by upregulated 
proteins enrichment analysis, as well as a potential role in fatty acid metabolism [Fig. 45, p. 70]. Further expression 
validation by Western blotting showed an increased expression of APOL2 in all 3 fibroblasts donors directly after 
Dox treatment (D1), whereas CES2 was barely detected in untreated cells (Untd.) [Fig. 46, p. 71]. 
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The decreased expression of CES2 during the development of SIPS shows that CES2 expression is due to Dox 
treatment. Nevertheless, siRNA-mediated knockdown of CES2 decreases senescent NHDF viability, suggesting 
a role in lipid or fatty acid metabolism. The role of CES2 in the context of senescence is unexplored. Nevertheless, 
further studies are required to assess whether CES2 is also increased when senescence is triggered using other 
induction methods, such as UV-B. 
 
6.4.3. Pituitary tumor-transforming gen 1 protein-interacting proteins (PTTG1IP) 
PTTG1IP is known to be involved in regulation of DNA Damage Response (DDR), important feature of SIPS229 
and is also involved in the regulation of protein ubiquitination and import into nucleus 229,230. Moreover, PTTG1IP 
is a p53 binding protein229, which was confirmed by the upregulated protein enrichment analysis [Fig. 48, p. 
72]. 
Expression validation by Western blotting confirmed that expression of PTTG1IP increases over time during 
the development of SIPS, and this among all donors [Fig. 49, p. 73]. Binding to p53, PTTG1IP might block its 
translocation into the nucleus, thus inhibiting apoptosis. M. P. Baar et al., recently described a similar mechanism, 
showing that the interaction of p53 with FOXO4 avoid apoptosis in senescent cells99. Further studies need to 
validate the interaction of PTTG1IP with p53, which could be a potential target for the elimination of senescent 
skin fibroblasts. 
 
6.4.4. MGARP protein (MGARP) 
MGARP is a mitochondrial-localized glutamic acid rich protein, hypostatized to play a role in protein targeting 
to mitochondrion and response to hypoxia, as well as in mitochondrial abundance and morphology. Upregulated 
proteins enrichment analysis confirmed its role in hypoxia, but not its implication in mitochondrial structure nor 
transport [Fig. 51, p. 74]. 
Data supporting its expression in senescent NHDF are conflictual; while 2D-LC-MS/MS identified MGARP on 
the basis of 6 unique peptides covering 47% of the protein, it was not detected by Western blotting in 3 different 
donors of NHDF (data not shown). Moreover, MGARP was not identified in skin cells (The Human Protein Atlas, 
2020). 
Electron microscopy of proliferating and senescent NHDF revealed decreased number and impaired structure 
of mitochondria in senescent NHDF [Fig. 52, p. 75]. 
The role of mitochondria in the context of senescence, autophagy and apoptosis is extensively studied55, 231-233. 
Wang et al. reported that mitochondrial membranes are depolarized in Dox-induced senescence234. Whether 
MGARP overexpression is sufficient to induce these changes, or if mitophagy is also involved remains to be 
determined. 
The relationship autophagy - senescence remains misunderstood, and seems to depend on the type of autophagy 
(selective VS basal), on the timing (when autophagy occurs) and on the location (where autophagy occurs). The 
graphical summary below shows what is already known about this relation, as well as the findings of this work 
[Fig. 55]. 
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Figure 55: Graphical summary. (Literature-left side): Although extensively studied in the context of 
senescence, the role of autophagy remains poorly understood. Selective autophagy (blue box) describes the 
specific recognition and elimination of cargos, mediated by ubiquitination and cargo receptors (such as p62, lamin 
B1 and NBR1). In competition with the proteasome system, selective autophagy can be pro-senescence (target 
degradation of Δ133p53α and nucleus portions) or anti-senescence (target degradation of GATA4 and 
dysfunctional mitochondria). General autophagy (pink box) refers to the non-specific breakdown of cellular 
components. General autophagy is an important actor of longevity. In this context, it can be anti-senescence 
(degrading cellular damages delays the onset of senescence) or pro-senescence (limiting accumulation of damages 
in senescence cells and helping for the production of the SASP). Interestingly, prolonged activation of general 
autophagy has been shown to trigger the senescence program. Contradictorily, silencing of key genes involved in 
autophagosome maturation (Atg5) also triggers senescence. Autophagy in cancer (grey box) has different 
outcome, as Atg5 inhibition changes the cell fate from senescence to apoptosis (APO, white box). Together, these 
observations suggest that the role of autophagy depends on the timing (early vs late role of autophagy), on the 
type of autophagy (specific vs general), on the cell type, on the location (TASCC vs nucleus vs cytoplasm) and 
on the context (normal vs cancer cells). 
(Findings-middle and right): Using 2D-LC-MS/MS analysis, we identified 230 upregulated protein in senescent 
skin fibroblasts. Subsequent analysis of these proteins led us to identify 260 enriched biological processes. Both 
upregulated proteins and enriched biological pathways are of interest for the identification of novel targets and 
elimination of senescent cells. In this context, we selected 4 upregulated proteins (APOL2, CES2, PTTG1IP and 
MGARP), involved in 4 different biological processes (respectively lipids metabolism, fatty acid metabolism, 
apoptosis and mitochondria biogenesis). Silencing of these genes in senescent skin fibroblasts engaged the 
apoptotic program (APO) in senescent NHDF (Bottom right). 
Autophagy-related biological processes accounted for approximatively 8% of the total identified by gene set 
enrichment analysis. When autophagy was stimulated prior to senescence induction, or during the development 
of stress-induced premature senescence, the onset of senescence was delayed, whereas its inhibition prior to 
senescence induction worthened the senescence phenotype. Interestingly, inhibition of autophagy during the 
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development of in senescence NHDF significantly decreased cell viability (right, pink box). Together, these data 
show that autophagy can be targeted for the specific elimination of senescent skin fibroblasts. 
Finally, we tested the ability of carbohydrate to modulate autophagy (upper right, yellow box). Depending on 
their nature, carbohydrate can either stimulate or inhibit autophagy. The exact mechanism by which this is 
regulated remains poorly understood. Weather carbohydrates-mediated modulation of autophagy, in the context 
of senescence, can trigger the apoptotic program remains to be determined and could be used for the elimination 
of senescent skin fibroblasts. 
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8. Appendix 
 
 
8.1. Supplementary graphs and tables 
Appendix 1 Downregulated proteins enrichment analysis 
 
No Description FDR q-value 
1 Defense response to virus 3.33E-10 
2 Response to virus 4.24E-08 
3 Negative regulation of viral process 6.64E-07 
4 Negative regulation of multi-organism process 2.47E-06 
5 Negative regulation of viral life cycle 3.93E-06 
6 Negative regulation of viral genome replication 1.20E-05 
7 Viral life cycle 6.92E-05 
8 Regulation of viral process 7.21E-05 
9 Regulation of viral life cycle 8.55E-05 
10 Regulation of viral genome replication 9.76E-05 
11 Viral genome replication 3.48E-04 
12 Interaction with host 6.29E-04 
13 Regulation by virus of viral protein levels in host cell 6.48E-04 
14 Entry into host 7.94E-04 
15 Entry into host cell 7.94E-04 
16 Positive regulation of defense response to virus by host 2.32E-03 
17 Viral entry into host cell 3.46E-03 
18 Regulation of defense response to virus by host 4.82E-03 
19 Hepatitis C 5.78E-03 
20 Multi-organism intracellular transport 9.31E-03 
21 Multi-organism cellular localization 9.31E-03 
22 Measles 1.25E-02 
23 Detection of virus 1.30E-02 
24 Cellular response to dsRNA 1.73E-02 
25 Negative regulation of viral entry into host cell 1.83E-02 
26 Regulation of defense response to virus 2.07E-02 
27 Influenza A 3.06E-02 
28 Positive regulation of viral genome replication 3.14E-02 
29 Response to exogenous dsRNA 3.37E-02 
30 Response to dsRNA 3.56E-02 
31 Positive regulation of viral life cycle 4.23E-02 
32 Negative regulation of defense response 4.71E-02 
33 Multi-organism localization 4.75E-02 
34 Multi-organism transport 4.75E-02 
Appendix 1a: List of BPs and pathways linked to viral defense enriched in senescent NHDF downregulated 
proteins set. Downregulated proteins were subjected to a gene set enrichment analysis. Mining GO:BP and 
REAC databases, a total of 681 biological processes were enriched, among which 34 were linked to viral defense. 
The table lists each BPs and its corresponding p-value (see section 4.8). 
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No Description FDR q-value 
1 response to type I interferon 1.54E-11 
2 type I interferon signaling pathway 2.14E-10 
3 cellular response to type I interferon 2.14E-10 
4 response to interferon-gamma 1.43E-05 
5 interferon-gamma-mediated signaling pathway 1.20E-04 
6 cellular response to interferon-gamma 3.48E-04 
7 negative regulation of plasminogen activation 3.48E-04 
8 response to interferon-beta 2.95E-03 
9 platelet degranulation 3.13E-03 
10 regulation of plasminogen activation 4.64E-03 
11 regulation of response to cytokine stimulus 4.68E-03 
12 positive regulation of response to cytokine stimulus 4.86E-03 
13 regulation of T cell activation via T cell receptor contact with antigen bound to MHC 
molecule on antigen presenting cell 
5.72E-03 
14 regulation of interferon-gamma-mediated signaling pathway 9.31E-03 
15 regulation of response to interferon-gamma 9.31E-03 
16 T cell activation via T cell receptor contact with antigen bound to MHC molecule on 
antigen presenting cell 
9.79E-03 
17 natural killer cell degranulation 1.03E-02 
18 regulation of cytokine-mediated signaling pathway 1.34E-02 
19 plasminogen activation 1.50E-02 
20 cellular response to interleukin-21 2.07E-02 
21 interleukin-21-mediated signaling pathway 2.07E-02 
22 response to interleukin-21 2.07E-02 
23 positive regulation of interferon-alpha production 2.11E-02 
24 positive regulation of cytokine-mediated signaling pathway 2.25E-02 
25 response to interferon-alpha 2.34E-02 
26 cellular response to interleukin-9 2.47E-02 
27 interleukin-9-mediated signaling pathway 2.47E-02 
28 cellular response to tumor necrosis factor 2.47E-02 
29 regulation of T cell activation 2.77E-02 
30 regulation of T cell receptor signaling pathway 2.79E-02 
31 interferon-alpha production 2.81E-02 
32 regulation of interferon-alpha production 2.81E-02 
33 response to tumor necrosis factor 2.81E-02 
34 response to interleukin-9 2.81E-02 
35 T cell activation 2.88E-02 
36 positive regulation of leukocyte mediated immunity 2.90E-02 
37 interleukin-35-mediated signaling pathway 3.10E-02 
38 interleukin-27-mediated signaling pathway 3.10E-02 
39 negative regulation of coagulation 3.14E-02 
40 astrocyte differentiation 3.24E-02 
41 cellular response to interleukin-6 3.37E-02 
42 interleukin-23-mediated signaling pathway 3.40E-02 
43 cyclooxygenase pathway 3.47E-02 
44 positive regulation of leukocyte degranulation 3.48E-02 
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45 antigen processing and presentation of peptide antigen via MHC class I 3.62E-02 
46 negative regulation of cell activation 3.75E-02 
47 response to interleukin-6 3.79E-02 
48 lymphocyte activation involved in immune response 3.81E-02 
49 negative regulation of innate immune response 3.92E-02 
50 positive regulation of astrocyte differentiation 4.37E-02 
51 negative regulation of defense response 4.71E-02 
52 antigen processing and presentation of exogenous peptide antigen via MHC class I, 
TAP-dependent 
4.92E-02 
53 negative regulation of immune response 4.95E-02 
Appendix 1b: List of BPs and pathways linked to immune response enriched in senescent NHDF 
downregulated proteins set. Downregulated proteins  were subjected to a gene set enrichment analysis. 
Mining GO:BP and REAC databases, a total of 681 biological processes were enriched, among which 53 were 
linked to immune response. The table lists each BPs and its corresponding p-value (see section 4.8). 
 
 
Appendix 2 Modulation of autophagy prior to senescence induction in WS1 fibroblasts 
 
Autophagy-untreated WS1 
Tukey's multiple 
comparisons test 
Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value 
D-1 vs. D0 -10050 -15055 to -5045 Yes *** 0.0001 
D-1 vs. D1 -11823 -16828 to -6818 Yes **** <0.0001 
D-1 vs. D2 -11582 -16587 to -6577 Yes **** <0.0001 
D-1 vs. D5 -15225 -20230 to -10220 Yes **** <0.0001 
D-1 vs. D8 -11146 -16151 to -6142 Yes **** <0.0001 
D-1 vs. D13 -13472 -18477 to -8467 Yes **** <0.0001 
D0 vs. D1 -1773 -6778 to 3232 No ns 0.8793 
D0 vs. D2 -1532 -6537 to 3472 No ns 0.934 
D0 vs. D5 -5176 -10180 to -170.7 Yes * 0.0406 
D0 vs. D8 -1097 -6102 to 3908 No ns 0.9865 
D0 vs. D13 -3422 -8427 to 1583 No ns 0.2937 
D1 vs. D2 240.4 -4764 to 5245 No ns >0.9999 
D1 vs. D5 -3403 -8408 to 1602 No ns 0.2992 
D1 vs. D8 676.2 -4329 to 5681 No ns 0.999 
D1 vs. D13 -1649 -6654 to 3356 No ns 0.9099 
D2 vs. D5 -3643 -8648 to 1362 No ns 0.2356 
D2 vs. D8 435.8 -4569 to 5441 No ns >0.9999 
D2 vs. D13 -1889 -6894 to 3115 No ns 0.8461 
D5 vs. D8 4079 -926 to 9084 No ns 0.1478 
D5 vs. D13 1754 -3251 to 6759 No ns 0.8844 
D8 vs. D13 -2325 -7330 to 2680 No ns 0.6925 
Appendix 2a: Modulation of autophagy prior to senescence induction. Statistical comparisons of SA-β-gal 
activity among time points in autophagy-untreated cells. D-1: after autophagy modulation & before senescence 
induction. D1 – D13: number ofdays following senescence induction in WS1. Means comparisons calculated by 
One-Way ANOVA. 
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Rap-treated WS1 
Tukey's multiple 
comparisons test 
Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value 
D-1 vs. D0 -2909 -9459 to 3640 No ns 0.7315 
D-1 vs. D1 -6763 -13312 to -213.3 Yes * 0.041 
D-1 vs. D2 -4413 -10962 to 2137 No ns 0.3081 
D-1 vs. D5 -6906 -13455 to -357 Yes * 0.0358 
D-1 vs. D8 -4037 -10586 to 2512 No ns 0.4002 
D-1 vs. D13 -11757 -18306 to -5208 Yes *** 0.0004 
D 0 vs. D1 -3853 -10402 to 2696 No ns 0.4504 
D0 vs. D2 -1503 -8052 to 5046 No ns 0.9829 
D0 vs. D5 -3997 -10546 to 2552 No ns 0.4109 
D0 vs. D8 -1127 -7677 to 5422 No ns 0.9962 
D0 vs. D13 -8848 -15397 to -2299 Yes ** 0.0057 
D1 vs. D2 2350 -4199 to 8899 No ns 0.8731 
D1 vs. D5 -143.7 -6693 to 6406 No ns >0.9999 
D1 vs. D8 2726 -3824 to 9275 No ns 0.7827 
D1 vs. D13 -4995 -11544 to 1555 No ns 0.1965 
D2 vs. D5 -2494 -9043 to 4056 No ns 0.8412 
D2 vs. D8 375.8 -6173 to 6925 No ns >0.9999 
D2 vs. D13 -7345 -13894 to -795.3 Yes * 0.0237 
D5 vs. D8 2869 -3680 to 9419 No ns 0.7429 
D5 vs. D13 -4851 -11400 to 1698 No ns 0.2205 
D8 vs. D13 -7720 -14270 to -1171 Yes * 0.0166 
Appendix 2b: Modulation of autophagy prior to senescence induction. Statistical comparisons of SA-β-gal 
activity among time points in autophagy-stimulated (Rap) cells. D-1: after autophagy modulation & before 
senescence induction. D1 – D13: number of days following senescence induction in WS1. Means comparisons 
calculated by One-Way ANOVA. 
 
 
Cq-treated WS1 
Tukey's multiple 
comparisons test 
Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value 
D-1 vs. D0 -11876 -18547 to -5205 Yes *** 0.0004 
D-1 vs. D1 -19991 -26662 to -13320 Yes **** <0.0001 
D-1 vs. D2 -23230 -29901 to -16560 Yes **** <0.0001 
D-1 vs. D5 -27468 -34138 to -20797 Yes **** <0.0001 
D-1 vs. D8 -25863 -32534 to -19193 Yes **** <0.0001 
D-1 vs. D13 -25087 -31758 to -18417 Yes **** <0.0001 
D0 vs. D1 -8115 -14786 to -1444 Yes * 0.0131 
D0 vs. D2 -11354 -18025 to -4684 Yes *** 0.0007 
D0 vs. D5 -15592 -22262 to -8921 Yes **** <0.0001 
D0 vs. D8 -13987 -20658 to -7317 Yes **** <0.0001 
D0 vs. D13 -13211 -19882 to -6541 Yes *** 0.0001 
D1 vs. D2 -3239 -9910 to 3431 No ns 0.6512 
D1 vs. D5 -7477 -14147 to -806 Yes * 0.0238 
102 
 
 
 
D1 vs. D8 -5872 -12543 to 798.1 No ns 0.1019 
D1 vs. D13 -5096 -11767 to 1574 No ns 0.1951 
D2 vs. D5 -4237 -10908 to 2433 No ns 0.3683 
D2 vs. D8 -2633 -9304 to 4037 No ns 0.8189 
D2 vs. D13 -1857 -8528 to 4813 No ns 0.9568 
D5 vs. D8 1604 -5066 to 8275 No ns 0.9785 
D5 vs. D13 2380 -4290 to 9051 No ns 0.8758 
D8 vs. D13 776 -5895 to 7447 No ns 0.9996 
Appendix 2c: Modulation of autophagy prior to senescence induction. Statistical comparisons of SA-β-gal 
activity among time points in autophagy-inhibited (Cq) cells. D-1: after autophagy modulation & before 
senescence induction. D1 – D13: number of days following senescence induction in WS1. Means comparisons 
calculated by One-Way ANOVA. 
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Appendix 3 Modulation of autophagy during the development of senescence in WS1 
 
Autophagy-untreated WS1 
Tukey's multiple 
comparisons test 
Mean Diff. 95% CI of diff. Significant? Summary Adjusted p-value 
D-1 vs. D0 -15311 -19322 to -11300 Yes **** <0.0001 
D-1 vs. D1 -12049 -16060 to -8038 Yes **** <0.0001 
D-1 vs. D2 -12442 -16453 to -8432 Yes **** <0.0001 
D-1 vs. D6 -12622 -16633 to -8612 Yes **** <0.0001 
D-1 vs. D9 -15358 -19369 to -11347 Yes **** <0.0001 
D-1 vs. D13 -17149 -21160 to -13138 Yes **** <0.0001 
D0 vs. D1 3262 -748.5 to 7273 No ns 0.1491 
D0 vs. D2 2869 -1142 to 6880 No ns 0.2512 
D0 vs. D6 2689 -1322 to 6700 No ns 0.3131 
D0 vs. D9 -46.89 -4058 to 3964 No ns >0.9999 
D0 vs. D13 -1838 -5849 to 2173 No ns 0.7048 
D1 vs. D2 -393.6 -4404 to 3617 No ns 0.9998 
D1 vs. D6 -573.6 -4584 to 3437 No ns 0.9986 
D1 vs. D9 -3309 -7320 to 701.6 No ns 0.1397 
D1 vs. D13 -5100 -9111 to -1089 Yes ** 0.0093 
D2 vs. D6 -180 -4191 to 3831 No ns >0.9999 
D2 vs. D9 -2916 -6926 to 1095 No ns 0.2367 
D2 vs. D13 -4707 -8717 to -695.8 Yes * 0.0171 
D6 vs. D9 -2736 -6746 to 1275 No ns 0.296 
D6 vs. D13 -4527 -8537 to -515.8 Yes * 0.0227 
D9 vs. D13 -1791 -5802 to 2220 No ns 0.7271 
Appendix 3a: Modulation of autophagy during the development of senescence in WS1. Statistical 
comparisons of SA-β-gal activity among time points in autophagy-untreated cells. D-1: before autophagy 
modulation & before senescence induction. D1 – D13: number of days following senescence induction in WS1. 
Means comparisons calculated by One-Way ANOVA. 
 
 
Rap-treated WS1 
Tukey's multiple 
comparisons test 
Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value 
D-1 vs. D0 -5311 -11996 to 1374 No ns 0.1655 
D-1 vs. D1 -6671 -13356 to 14.33 No ns 0.0507 
D-1 vs. D2 -6500 -13185 to 185.3 No ns 0.0591 
D-1 vs. D6 -15877 -22563 to -9192 Yes **** <0.0001 
D-1 vs. D9 -12924 -19609 to -6238 Yes *** 0.0002 
D-1 vs. D13 -17928 -24614 to -11243 Yes **** <0.0001 
D0 vs. D1 -1360 -8045 to 5325 No ns 0.9908 
D0 vs. D2 -1189 -7874 to 5496 No ns 0.9955 
D0 vs. D6 -10566 -17251 to -3881 Yes ** 0.0014 
D0 vs. D9 -7613 -14298 to -927.3 Yes * 0.0213 
D0 vs. D13 -12617 -19303 to -5932 Yes *** 0.0002 
D1 vs. D2 171 -6514 to 6856 No ns >0.9999 
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D1 vs. D6 -9206 -15892 to -2521 Yes ** 0.0048 
D1 vs. D9 -6253 -12938 to 432.6 No ns 0.0738 
D1 vs. D13 -11257 -17943 to -4572 Yes *** 0.0008 
D2 vs. D6 -9377 -16063 to -2692 Yes ** 0.0041 
D2 vs. D9 -6424 -13109 to 261.6 No ns 0.0633 
D2 vs. D13 -11428 -18114 to -4743 Yes *** 0.0007 
D6 vs. D9 2953 -3732 to 9639 No ns 0.7361 
D6 vs. D13 -2051 -8736 to 4634 No ns 0.9334 
D9 vs. D13 -5005 -11690 to 1681 No ns 0.2116 
Appendix 3b: Modulation of autophagy during the development of senescence in WS1. Statistical 
comparisonsof SA-β-galactivity amongtime pointsinautophagy-stimulated(Rap) cells. D-1: before autophagy 
modulation & before senescence induction. D1 – D13: number of days following senescence induction in WS1. 
Means comparisons calculated by One-Way ANOVA. 
 
 
Cq-treated WS1 
Tukey's multiple 
comparisons test 
Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value 
D-1 vs. D0 -5311 -9024 to -1599 Yes ** 0.0035 
D-1 vs. D1 1982 -1730 to 5694 No ns 0.555 
D-1 vs. D2 2876 -836.4 to 6588 No ns 0.1842 
D-1 vs. D6 6666 2953 to 10378 Yes *** 0.0004 
D-1 vs. D9 -488.3 -4201 to 3224 No ns 0.9991 
D-1 vs. D13 -13250 -16962 to -9537 Yes **** <0.0001 
D0 vs. D1 7293 3581 to 11005 Yes *** 0.0002 
D0 vs. D2 8187 4475 to 11900 Yes **** <0.0001 
D0 vs. D6 11977 8265 to 15689 Yes **** <0.0001 
D0 vs. D9 4823 1110 to 8535 Yes ** 0.0078 
D0 vs. D13 -7939 -11651 to -4226 Yes **** <0.0001 
D1 vs. D2 894.1 -2818 to 4607 No ns 0.9783 
D1 vs. D6 4684 971.5 to 8396 Yes ** 0.0099 
D1 vs. D9 -2470 -6183 to 1242 No ns 0.3205 
D1 vs. D13 -15232 -18944 to -11519 Yes **** <0.0001 
D2 vs. D6 3790 77.39 to 7502 Yes * 0.044 
D2 vs. D9 -3364 -7077 to 348.1 No ns 0.0876 
D2 vs. D13 -16126 -19838 to -12413 Yes **** <0.0001 
D6 vs. D9 -7154 -10867 to -3442 Yes *** 0.0002 
D6 vs. D13 -19915 -23628 to -16203 Yes **** <0.0001 
D9 vs. D13 -12761 -16474 to -9049 Yes **** <0.0001 
Appendix 3c: Modulation of autophagy during the development of senescence in WS1. Statistical 
comparisons of SA-β-gal activity among time points in autophagy-inhibited (Cq) cells. D-1: before autophagy 
modulation & before senescence induction. D1 – D13: number of days following senescence induction in WS1. 
Means comparisons calculated by One-Way ANOVA. 
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Appendix 4: SA-β-gal staining of senescent WS1 treated with Rap, Cq or left untreated for 1 day (D15) and 7 
days (D22). Blue staining indicates senescent cells. Representative figures from three biological replicates are 
shown. Scalebar: 100 µM 
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3d inhibition of autophagy 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI of diff. Significant? Summary Adjusted P Value 
Untd vs. Wort 18971 7752 to 30190 Yes **** <0.0001 
Untd vs. Cq 34489 23270 to 45708 Yes **** <0.0001 
Untd vs. Atg5 40116 28897 to 51335 Yes **** <0.0001 
Untd vs. Atg7 47187 35968 to 58406 Yes **** <0.0001 
Untd vs. Atg5+Cq 58197 46978 to 69416 Yes **** <0.0001 
Untd vs. Atg7+ Cq 60910 49690 to 72129 Yes **** <0.0001 
Wort vs. Cq 15518 4299 to 26737 Yes ** 0.0017 
Wort vs. Atg5 21146 9926 to 32365 Yes **** <0.0001 
Wort vs. Atg7 28216 16997 to 39435 Yes **** <0.0001 
Wort vs. Atg5+ Cq 39226 28007 to 50445 Yes **** <0.0001 
Wort vs. Atg7+ Cq 41939 30720 to 53158 Yes **** <0.0001 
Cq vs. Atg5 5627 -5592 to 16846 No ns 0.7186 
Cq vs. Atg7 12698 1479 to 23917 Yes * 0.0172 
Cq vs. Atg5+ Cq 23708 12489 to 34927 Yes **** <0.0001 
Cq vs. Atg7+ Cq 26420 15201 to 37639 Yes **** <0.0001 
Atg5 vs. Atg7 7071 -4148 to 18290 No ns 0.4665 
Atg5 vs. Atg5+ Cq 18081 6862 to 29300 Yes *** 0.0002 
Atg5 vs. Atg7+ Cq 20793 9574 to 32012 Yes **** <0.0001 
Atg7 vs. Atg5+ Cq 11010 -208.8 to 22229 No ns 0.0576 
Atg7 vs. Atg7+ Cq 13723 2504 to 24942 Yes ** 0.0077 
Atg5+ Cq vs. Atg7+ 
Cq 
2712 -8507 to 13931 No ns 0.989 
Appendix 5a: Viability of senescent NHDF following inhibition of autophagy. Autophagy was inhibited 
using Wortmannin (Wort), chloroquine (Cq) and siRNA targeting Atg5/7. Cell viability assessed by ATP assay 
after 3 days treatment. Mean comparisons calculated using One-Way ANOVA. 
 
6d inhibition of autophagy 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI of diff. Significant? Summary Adjusted P Value 
Untd vs. Wort 44534 37857 to 51210 Yes **** <0.0001 
Untd vs. Cq 59512 52835 to 66188 Yes **** <0.0001 
Untd vs. Atg5 60692 54015 to 67368 Yes **** <0.0001 
Untd vs. Atg7 66615 59939 to 73292 Yes **** <0.0001 
Untd vs. Atg5+Cq 69755 63078 to 76431 Yes **** <0.0001 
Untd vs. Atg7+ Cq 71159 64483 to 77836 Yes **** <0.0001 
Wort vs. Cq 14978 8301 to 21654 Yes **** <0.0001 
Wort vs. Atg5 16158 9481 to 22834 Yes **** <0.0001 
Wort vs. Atg7 22082 15405 to 28758 Yes **** <0.0001 
Wort vs. Atg5+ Cq 25221 18545 to 31897 Yes **** <0.0001 
Wort vs. Atg7+ Cq 26626 19949 to 33302 Yes **** <0.0001 
Cq vs. Atg5 1180 -5496 to 7857 No ns 0.998 
Cq vs. Atg7 7104 427.5 to 13780 Yes * 0.0302 
Cq vs. Atg5+ Cq 10243 3567 to 16920 Yes *** 0.0004 
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Cq vs. Atg7+ Cq 11648 4971 to 18324 Yes **** <0.0001 
Atg5 vs. Atg7 5924 -752.7 to 12600 No ns 0.1129 
Atg5 vs. Atg5+ Cq 9063 2387 to 15740 Yes ** 0.0022 
Atg5 vs. Atg7+ Cq 10468 3791 to 17144 Yes *** 0.0003 
Atg7 vs. Atg5+ Cq 3139 -3537 to 9816 No ns 0.7745 
Atg7 vs. Atg7+ Cq 4544 -2132 to 11220 No ns 0.3733 
Atg5+ Cq vs. Atg7+ 
Cq 
1405 -5272 to 8081 No ns 0.9948 
Appendix 5b: Viability of senescent NHDF following inhibition of autophagy. Autophagy was inhibited 
using Wortmannin (Wort), chloroquine (Cq) and siRNA targeting Atg5/7. Cell viability assessed by ATP assay 
after 6 days treatment. Mean comparisons calculated using One-Way ANOVA. 
 
9d inhibition of autophagy 
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.00% CI of diff. Significant? Summary Adjusted P Value 
Untd vs. Wort 38542 28059 to 49024 Yes **** <0.0001 
Untd vs. Cq 71009 60527 to 81492 Yes **** <0.0001 
Untd vs. Atg5 68837 58355 to 79320 Yes **** <0.0001 
Untd vs. Atg7 74814 64332 to 85297 Yes **** <0.0001 
Untd vs. Atg5+ Cq 74907 64424 to 85389 Yes **** <0.0001 
Untd vs. Atg7+ Cq 75109 64626 to 85591 Yes **** <0.0001 
Wort vs. Cq 32468 21985 to 42950 Yes **** <0.0001 
Wort vs. Atg5 30295 19813 to 40778 Yes **** <0.0001 
Wort vs. Atg7 36273 25790 to 46755 Yes **** <0.0001 
Wort vs. Atg5+ Cq 36365 25882 to 46847 Yes **** <0.0001 
Wort vs. Atg7+ Cq 36567 26085 to 47049 Yes **** <0.0001 
Cq vs. Atg5 -2172 -12655 to 8310 No ns 0.9952 
Cq vs. Atg7 3805 -6678 to 14287 No ns 0.9202 
Cq vs. Atg5+ Cq 3897 -6585 to 14380 No ns 0.9114 
Cq vs. Atg7+ Cq 4099 -6383 to 14582 No ns 0.89 
Atg5 vs. Atg7 5977 -4505 to 16460 No ns 0.5851 
Atg5 vs. Atg5+ Cq 6070 -4413 to 16552 No ns 0.5675 
Atg5 vs. Atg7+ Cq 6272 -4211 to 16754 No ns 0.5291 
Atg7 vs. Atg5+ Cq 92.38 -10390 to 10575 No ns >0.9999 
Atg7 vs. Atg7+ Cq 294.5 -10188 to 10777 No ns >0.9999 
Atg5+ Cq vs. Atg7+ 
Cq 
202.1 -10280 to 10685 No ns >0.9999 
Appendix 5c: Viability of senescent NHDF following inhibition of autophagy. Autophagy was inhibited using 
Wortmannin (Wort), chloroquine (Cq) and siRNA targeting Atg5/7. Cell viability assessed by ATP assay after 9 
days treatment. Mean comparisons calculated using One-Way ANOVA. 
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Appendix 5d: Viability of senescent NHDF following inhibition of autophagy. Autophagy was inhibited using 
Wortmannin (Wort), chloroquine (Cq) and siRNA targeting Atg5/7. Cell viability evaluated by counting the 
number of floating (dead) cells in culture medium after 3-, 6- and 9 days treatment. 
 
 
Appendix 6 Identification of APOL2, CES2, PTTG1IP and MGARP by 2D-LC-MS/MS analysis 
 
Conf Sequence Accession numbers MC II [%] RT [min] 
High [R].aLAEEVEQVHR.[G] Q9BQE5 0 8 151.42 
High [R].aLAEEVEQVHR.[G] Q9BQE5 0 3 151.60 
High [R].nLDQSGTNVAk.[V] Q9BQE5 0 0 86.66 
High [R].iSAEGGEQVER.[V] Q9BQE5 0 0 82.93 
High [R].aLAEEVEQVHR.[G] Q9BQE5 0 3 151.78 
High [R].aLAEEVEQVHR.[G] Q9BQE5 0 16 151.97 
High [R].iSAEGGEQVER.[V] Q9BQE5 0 0 35.30 
High [R].aLAEEVEQVHR.[G] Q9BQE5 0 25 151.26 
High [K].sESAEELk.[K] Q9BQE5 0 0 103.54 
High [K].sESAEELk.[K] Q9BQE5 0 0 103.77 
High [K].sESAEELk.[K] Q9BQE5 0 6 103.97 
High [K].sESAEELk.[K] Q9BQE5 0 4 40.54 
High [K].sESAEELk.[K] Q9BQE5 0 12 104.18 
Appendix 6a: Peptide-spectrum matches from APOL2 identification by 2D-LC-MSMS. Conf: confidence, 
MC: miss cleavage, II: isolation interference and RT: retention time. 
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Conf Sequence Accession numbers MC II [%] RT [min] 
High [K].skEEILAINkPFk.[M] O00748 1 37 144.58 
High [K].fTEEEEQLSR.[K] O00748 0 50 160.77 
High [K].iQELEEPEER.[H] O00748 0 5 166.35 
High [K].fTEEEEQLSR.[K] O00748 0 0 160.43 
High [K].iQELEEPEER.[H] O00748 0 19 166.16 
High [K].iQELEEPEER.[H] O00748 0 0 166.59 
High [K].fTEEEEQLSR.[K] O00748 0 7 161.17 
High [K].fTEEEEQLSR.[K] O00748 0 6 61.58 
High [K].iQELEEPEER.[H] O00748 0 4 166.66 
High [K].iQELEEPEER.[H] O00748 0 0 166.32 
High [K].fTEEEEQLSR.[K] O00748 0 23 61.71 
Appendix 6b: Peptide-spectrum matches from CES2 identification by 2D-LC-MSMS. Conf: confidence, 
MC: miss cleavage, II: isolation interference and RT: retention time. 
 
 
Conf Sequence Accession numbers MC II [%] RT [min] 
High ACLDYPVTSVLPPASLCK P53801 0 12 180.4575 
High ACLDYPVTSVLPPASLCK P53801 0 4 180.659 
High ACLDYPVTSVLPPASLCK P53801 0 5 180.84 
High ACLDYPVTSVLPPASLCK P53801 0 4 180.9427 
High ACLDYPVTSVLPPASLCK P53801 0 8 181.023 
High ACLDYPVTSVLPPASLCK P53801 0 3 181.1559 
High ACLDYPVTSVLPPASLCK P53801 0 11 181.2019 
High ACLDYPVTSVLPPASLCK P53801 0 11 181.3856 
High ACLDYPVTSVLPPASLCK P53801 0 7 181.5712 
High ACLDYPVTSVLPPASLCK P53801 0 0 180.9803 
High ACLDYPVTSVLPPASLCK P53801 0 0 180.7116 
Appendix 6c: Peptide-spectrum matches from PTTG1IP identification by 2D-LC-MSMS. Conf: 
confidence, MC: miss cleavage, II: isolation interference and RT: retention time. 
 
 
Conf Sequence Accession 
numbers 
MC II [%] RT 
[min] 
High EASACPGHVEAAPETTAVSAETGPEVTDAAAR Q8TDB4 0 0 174.9751 
High EASACPGHVEAAPETTAVSAETGPEVTDAAAR Q8TDB4 0 0 174.9979 
High EASACPGHVEAAPETTAVSAETGPEVTDAAAR Q8TDB4 0 0 175.2095 
High EASACPGHVEAAPETTAVSAETGPEVTDAAAR Q8TDB4 0 0 175.2121 
High EASACPGHVEAAPETTAVSAETGPEVTDAAAR Q8TDB4 0 0 175.3998 
High EASACPGHVEAAPETTAVSAETGPEVTDAAAR Q8TDB4 0 0 61.5678 
High ETTEVNPETTPEVTNAALDEAVTIDNDK Q8TDB4 0 0 129.5852 
High ETTEVNPETTPEVTNAALDEAVTIDNDK Q8TDB4 0 0 129.7975 
High ETTEVNPETTPEVTNAALDEAVTIDNDKDTTK Q8TDB4 1 0 124.8301 
High ETTEVNPETTPEVTNAALDEAVTIDNDK Q8TDB4 0 0 129.6554 
High ETTEVNPETTPEVTNAALDEAVTIDNDK Q8TDB4 0 0 129.4861 
High EASACPGHVEAAPETTAVSAETGPEVTDAAAR Q8TDB4 0 0 61.4524 
High ETTEVNPETTPEVTNAALDEAVTIDNDKDTTK Q8TDB4 1 0 125.1581 
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High ETTEVNPETTPEVTNAALDEAVTIDNDK Q8TDB4 0 0 129.4397 
High ETTEVNPETTPEVTNAALDEAVTIDNDK Q8TDB4 0 0 129.3991 
High ETTEVNPETTPEVTNAALDEAVTIDNDK Q8TDB4 0 0 129.8562 
High ASSEAPEELIVEAEVVDAEESPSATVVVIK Q8TDB4 0 17 177.1379 
High TVTSDQAK Q8TDB4 0 35 64.4283 
High AEIHPFQGEK Q8TDB4 0 51 99.1924 
Appendix 6d: Peptide-spectrum matches from MGARP identification by 2D-LC-MSMS. Conf: confidence, 
MC: miss cleavage, II: isolation interference and RT: retention time. 
 
 
Appendix 7 Trehalose-mediated stimulation of autophagy in senescent NHDF 
 
 
 
Appendix 7: 3 weeks old senescent NHDF viability following 3-, 6- and 12 days of trehalose treatment. 
3 weeks old senescent NHDF were treated with 50, 100 and 200 mM trehalose for 3, 6 and 12 days. Cell 
viability was assessed by ATP assay. Values were obtained from n ≥ 6 biological replicates. Means ± SEM are 
shown. Adjusted p-values of Tukey’s multiple comparison test: (****): < 0.0001, (**): < 0.01, (ns): not 
significant. 
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8.2. Abbreviations 
 
Abbreviation Definition 
ATG12 Autophagy related protein 12 
2D-DIGE 2-dimensional differential gel electrophoresis 
2D-GE 2-dimensional gel electrophoresis 
2D-LC-MS/MS 2-dimensional liquid chromatography tandem mass spectrometry 
Akt Protein Kinase B 
AMPK Adenosine monophosphate-activated kinase 
ANOVA Analysis of variance 
AP Autophagy 
APOL2 Apolipoprotein 2 
ATG5 Autophagy related protein 5 
ATG7 Autophagy related protein 7 
ATP Adenosine triphosphate 
AV Autophagic vesicle 
BCL-2 B-cell lymphoma 2 
BPs Biological processes 
BSA Bovine serum albumin 
C/EBP CCAAT/Enhancer-Binding-Protein 
CDK Cyclin-dependent kinase 
CES2 Cocaine esterase 2 
CMA Chaperone-mediated autophagy 
COVID-19 Coronavirus disease 2019 
Cq Chloroquine 
DC Dendritic cell 
DDR DNA damage response 
DEPs Differentially expressed proteins 
DETC Dendritic epidermal T cell 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
Dox Doxorubicin 
E2F Transcription factor E2F 
ECM Extracellular matrix 
EM Enrichment map 
FDR False discovery rate 
FoxO3 Forkhead-box-protein O3 
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GATA4 Transcription factor GATA-4 
GO:BP Gene Ontology, Biological Processes database 
GSEA Gene set enrichment analysis 
HMDM2 Human mouse double minute 2 
HRP Horseradish peroxidase 
HSC70 Heat shock protein 70 
HSP Heat shock protein 
IIS Insulin and IGF-1 signaling 
IL-6 Interleukin 6 
IL-8 Interleukin 8 
ILC Innate lymphoid cell 
K Amino acid Lysin 
LAMP2A Lysosome-associated membrane protein 2 
LC3 Microtubule-associated protein light chain 3 
LC3i Microtubule-associated protein light chain 3, cytosolic form 
LC3ii Microtubule-associated protein light chain 3, membrane-bound 
LDH Lactate dehydrogenase 
MEM Minimum essential medium 
MGARP MGARP protein 
MMP Matrix metal-protease 
mTOR Mechanistic target of rapamycin 
mTORC1 Mechanistic target of rapamycin complex 1 
mTORC2 Mechanistic target of rapamycin complex 2 
MW Molecular weight 
NC Non-senescent 
NF-κB Nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
NHDF Normal human dermal fibroblasts 
NT No treatment 
OIS Oncogene-induced senescence 
p14ARF ARF tumor suppressor 
p16 INK4A Cyclin-dependent kinase inhibitor 2A 
p21 Cyclin-dependent kinase inhibitor 1 or CDK-interacting protein 1 
p53 Cellular tumor antigen p53 
p62 Sequestosome 1 
pDC Plasmacytoid dendritic cell 
PE Phosphatidlyethanolamine 
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PI3KIII Class III PI 3-kinase 
PSM Peptide-spectrum match 
PTTG1IP Pituitary Tumor-Transforming Gene 1 Protein-Interacting Protein 
pU Poly-ubiquitination 
PVDF Polyvinylidene difluoride 
Rap Rapamycin 
Raptor Regulatory associated protein of mTOR 
Rb Retinoblastoma 
REAC Reactrome database 
RFU Relative fluorescent unit 
Rictor Rapamycin-insensitive companion of mTOR 
ROS Reactive oxygen species 
RT Room temperature 
S6K1 p70 ribosomal protein S6 kinase 1 
SA-b-gal Senescence-associates beta galactosidase 
SAHF Senescence-associated heterochromatin foci 
SASP Senescence-associated secretory phenotype 
SC Senescent 
SDS-PAGE Sodium dodecyl sulfate - polyacrylamide gel electrophoresis 
SEM Standard error mean 
SIPS Stress induced premature senescence 
siRNA Small interfering RNA 
TASCC TOR-autophagy spatial coupling compartment 
TBS Tris-buffered saline 
TIMP Tissue inhibitor of metalloproteases 
ULK1 Unc-51-like kinase 1 
UPS Ubiquitin-proteasome system 
UT Untreated 
UV Ultraviolet 
Wort Wortmannin 
X-Gal 5-bromo-4-chloro-3-indoyl b-D-galactopyranoside 
γH2AX Phosphorylated form of the histone H2AX 
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